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A B S T R A C T
Background
Between 4% and 25% of school-aged children at some stage complain of recurrent abdominal pain (RAP) of suHicient severity to interfere
with their daily lives. When no clear organic cause is found, the children are managed with reassurance and simple measures; a large range
of pharmacological interventions have been recommended for use in these children.
Objectives
To determine the eHectiveness of pharmacological interventions for RAP in children of school age.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, and eight other electronic databases
up to June 2016. We also searched two trials registers and contacted researchers of published studies.
Selection criteria
Randomised controlled trials involving children aged five to 18 years old with RAP or an abdominal pain-related functional gastrointestinal
disorder, as defined by the Rome III criteria (Rasquin 2006). The interventions were any pharmacological intervention compared to placebo,
no treatment, waiting list, or standard care. The primary outcome measures were pain intensity, pain duration or pain frequency, and
improvement in pain. The secondary outcome measures were school performance, social or psychological functioning, and quality of daily
life.
Data collection and analysis
Two review authors independently screened titles, abstracts, and potentially relevant full-text reports for eligible studies. Two review
authors extracted data and performed a 'Risk of bias' assessment. We used the GRADE approach to rate the overall quality of the evidence.
We deemed a meta-analysis to be not appropriate as the studies were significantly heterogeneous. We have consequently provided a
narrative summary of the results.
Main results
This review included 16 studies with a total of 1024 participants aged between five and 18 years, all of whom were recruited from paediatric
outpatient clinics. Studies were conducted in seven countries: seven in the USA, four in Iran, and one each in the UK, Switzerland, Turkey, Sri
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Lanka, and India. Follow-up ranged from two weeks to four months. The studies examined the following interventions to treat RAP: tricyclic
antidepressants, antibiotics, 5-HT4 receptor agonists, antispasmodics, antihistamines, H2 receptor antagonists, serotonin antagonists,
selective serotonin re-uptake inhibitors, a dopamine receptor antagonist, and a hormone. Although some single studies reported that
treatments were eHective, all of these studies were either small or had key methodological weaknesses with a substantial risk of bias. None
of these 'positive' results have been reproduced in subsequent studies. We judged the evidence of eHectiveness to be of low quality. No
adverse eHects were reported in these studies.
Authors' conclusions
There is currently no convincing evidence to support the use of drugs to treat RAP in children. Well-conducted clinical trials are needed to
evaluate any possible benefits and risks of pharmacological interventions. In practice, if a clinician chooses to use a drug as a 'therapeutic
trial', they and the patient need to be aware that RAP is a fluctuating condition and any 'response' may reflect the natural history of the
condition or a placebo eHect, rather than drug eHicacy.
P L A I N   L A N G U A G E   S U M M A R Y
Drug treatment of recurrent abdominal pain in children
Review question
Do medications improve the pain or other symptoms experienced by children with recurrent abdominal pain (RAP)?
Background
Recurrent abdominal pain in childhood is a term used to describe unexplained episodes of tummy pain for which no cause can be found.
The pain is oNen accompanied by other symptoms, such as diarrhoea or facial pallor. Some researchers have therefore classified diHerent
syndromes of unexplained pain according to these other associated symptoms. Recurrent abdominal pain is common in children. It is
likely that the underlying cause or trigger diHers among children.
Study characteristics
We searched the scientific literature worldwide up to June 2016 for research studies of drug treatments for children with RAP. We found
16 studies that met our criteria, examining antidepressants, antibiotics, antihistamines, antispasmodics, a dopamine receptor antagonist,
and a hormone treatment. Fourteen studies compared drug treatments to a placebo, and two to usual medical care. The trials were carried
out in seven countries: seven in the USA, four in Iran, one in the UK, one in Switzerland, one in Turkey, one in Sri Lanka, and one in India.
The studies included a total of 1024 children aged between five and 18 years. All children were recruited from outpatient clinics. Follow-
up lasted between two weeks and four months.
Key results
This review suggests there is no evidence for the use of medications to improve symptoms or the child's quality of life. Consequently, if
medications are prescribed, this should be done within a well-conducted clinical trial. If a medication is prescribed to a child with RAP,
it must be remembered that RAP varies with time, and therefore any improvement or worsening may due to the natural history of the
condition rather than a medication response.
Quality of evidence
Many of the studies had some weaknesses in their design and how they were reported, therefore the overall quality of the evidence for
medications in RAP is low. The studies with better methods included few children and have not been reproduced by other researchers since.
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Summary of findings for the main comparison.   Antispasmodics compared to placebo for recurrent abdominal pain
Antispasmodics compared to placebo for recurrent abdominal pain
Patient or population: school-aged children (5 to 18 years of age) with recurrent abdominal pain
Settings: hospital paediatric outpatient clinics
Intervention: antispasmodic drugs
Comparison: placebo
Illustrative comparative risks* (SD)
Assumed risk Corresponding risk
Outcomes
Placebo Intervention
Relative ef-
fect (95% CI)
Number of
participants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain duration (mean pain du-
ration, assessed at 4 weeks)
The mean duration of pain in the
control group was 6.17 (± 11.61).
The mean duration of
pain in the interven-
tion group was51.6 (±
23.74).
MD -25.4
(-35.5 to -15.3)
120 (1) ⊕⊝⊝⊝
Very low1
Asgarshirazi 2015
No evidence of
efficacy
Pain improvement (clinician
judged, assessed at 2 weeks)
9 of 21 children in the control group
had an improvement in pain.
15 of 21 children in
the intervention group
had an improvement
in pain.
OR 3.33 (0.93
to 12.01)
42 (1) ⊕⊝⊝⊝
Very low2
Kline 2001
No evidence of
efficacy
Pain frequency (episodes of
pain in 4 weeks, assessed after
4 weeks)
The mean number of episodes of
pain in the control group was 21.6
(32.4).
The mean number of
episodes of pain in the
intervention group
was10.3 (14).
MD 11.3 (2.4
to 20.1)
132 (1) ⊕⊝⊝⊝
Very low3
Narang 2015
No evidence of
efficacy
Pain improvement (self report-
ed response to treatment, as-
sessed at 4 weeks)
The response to treatment in the
control group was 30.3%.
The response to treat-
ment in the interven-
tion group was 40.6%.
OR 1.6 (0.7 to
3.4)
115 (1) ⊕⊕⊝⊝
Low4
Pourmoghaddas
2014
No evidence of
efficacy
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; OR: odds ratio; SD: standard deviation
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded for low methodological quality due to single, small study; risk of bias from incomplete outcome data and diHerential loss of participants between groups. The
placebo diHered in preparation and dose timing compared to the intervention drug.
2Downgraded for low methodological quality due to single, small study; risk of bias from selective outcome reporting and short follow-up.
3Downgraded for low methodological quality due to single, small study; risk of bias from selective outcome reporting and the method of altering the drug doses.
4Downgraded for single, small study. Not duplicated.
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B A C K G R O U N D
Description of the condition
This review is an update of a previously published review in the
Cochrane Library on 'Pharmacological interventions for recurrent
abdominal pain (RAP) and irritable bowel syndrome (IBS) in
childhood' (Huertas-Ceballos 2008a). Recurrent abdominal pain
(RAP) is a common problem in paediatric practice. It has been
suggested that 4% to 25% of school-aged children at some stage
suHer from RAP that interferes with their activities of daily living
(Abu-Arafeh 1995; Apley 1958; Faull 1986; Williams 1996; Øster
1972). Recurrent abdominal pain is oNen regarded as a relatively
benign condition, but it is important to note the associated
morbidity and anxiety it causes for children and carers. The
condition is associated with school absences, hospital admissions,
and, on occasion, unnecessary surgical intervention (ScharH 1997;
Stickler 1979; Størdal 2005; Walker 1998). Symptoms sometimes
continue into adulthood (Apley 1975). The abdominal pain is
commonly associated with other symptoms, including headaches,
recurrent limb pains, pallor, and vomiting (Abu-Arafeh 1995; Apley
1958; Faull 1986; Hyams 1995; Stickler 1979; Stone 1970; Øster
1972).
It is generally accepted that RAP in children represents a group
of functional gastrointestinal disorders with an unclear aetiology.
Children suHer either chronic or recurrent gastrointestinal
symptoms that are not explained by a structural, biochemical, or
inflammatory process. Apley first sought to define the condition in
the 1950s, suggesting that the diagnostic label should be based on
the presence of at least three episodes of severe abdominal pain
(oNen, but not necessarily, with associated systemic symptoms)
over three months, with no established organic cause (Apley
1958). More recently, an international consensus definition with a
symptom-based classification system with specific categories for
paediatric presentations has been produced, known as the Rome III
criteria (Rasquin 2006). We have used RAP throughout this review
as an umbrella term to refer to the five categories included within
this classification, which are: functional dyspepsia, irritable bowel
syndrome (IBS), abdominal migraine, functional abdominal pain,
and functional abdominal pain syndrome. It should be noted that
the pain classification for each of the Rome III diagnoses is defined
by at least one episode per week for at least two months; this varies
from Apley's original definition of RAP (Apley 1958). The Rome
classification is not based on known pathophysiological diHerences
between the conditions, but rather on the constellation of clinical
features. It remains unclear the extent to which separating children
into these categories defines groups that are distinct clinical
entities likely to respond diHerently to treatment. Nonetheless,
this classification has been welcomed following the historical
use of diverse terms, some implying causation. These include
abdominal migraine (Bain 1974; Farquar 1956; Hockaday 1992;
Symon 1986), abdominal epilepsy (Stowens 1970), the irritable
bowel syndrome in childhood (Stone 1970), allergic-tension-fatigue
syndrome (Sandberg 1973; Speer 1954), neurovegetative dystonia
(Peltonen 1970; Rubin 1967), functional gastrointestinal disorder
(Drossman 1995), and the irritated colon syndrome (Harvey 1973;
Painter 1964).
There is no consensus about which of the numerous proposed
causal pathways result in the heterogeneous presentations of
chronic abdominal pain, although it has been suggested that
physical, emotional, and environmental factors may contribute
to the manifestation of unexplained abdominal pain. When
considering the diverse proposed mechanisms, it is unsurprising
that a variety of treatments have been suggested. The treatment
approaches can be grouped into pharmacological, dietary, or
psychosocial (psychological, behavioural, or both). Reviews of
the eHectiveness of psychosocial and dietary interventions for
RAP (Huertas-Ceballos 2008b; Huertas-Ceballos 2009), published in
2008 and 2009, have been updated as companions to this updated
review (Abbott 2017; Newlove-Delgado in press, respectively).
Description of the intervention
A range of pharmacological treatments have been tried and
tested for RAP in childhood: analgesics, dicyclomine (Edwards
1994), pizotifen (Christensen 1995; Symon 1995), herbal extracts
(Zhang 1991), and many other drugs (Bain 1974; Worawattanakul
1999). A number of randomised controlled trials have reported
on the use of peppermint oil for IBS in adults (Grigoleit 2005),
the results of which have been interpreted as suggesting it to
be a beneficial intervention. However, an earlier review reached
no clear conclusion on eHicacy due to poor methodological
quality of the included studies (Pittler 1998). Other possible causal
factors have been postulated, including food allergies (Poley 1973),
reaction to food additives (Anonymous 1984), infectious agents
like Helicobacter pylori, and parasitic infestation (Heldenberg 1995;
Primelles 1990; Wardhan 1993).
How the intervention might work
The aetiology of abdominal pain-related functional gastrointestinal
disorders is unclear. It has been suggested that visceral
hypersensitivity (Di Lorenzo 2001; Van Ginkel 2001), autonomic
dysfunction (Good 1995), and gut dysmotility may contribute,
which may be initiated by an inflammatory, infective, traumatic, or
allergic trigger (Mayer 2002; Milla 2001).
Conventional analgesics have been proposed to work by
interrupting these abnormal physiological pain responses, which
become pathological. Antispamodics have been proposed to alter
gut dysmotility, including peppermint oil, which has antispasmodic
actions (Hills 1991). Serotonin (5-hydroxytryptamine) agonists may
relieve symptoms by causing vasoconstriction and stimulation
of the release of other vasoactive substances, thus inhibiting
neurogenic inflammation; this has been found in migraine
headaches (Goadsby 2000). Antidepressants treat the associated
symptoms, and there is evidence of eHectiveness in treating IBS in
adults (Ruepert 2011).
Why it is important to do this review
Recurrent abdominal pain in children is very common, and in
daily clinical practice there is no consensus on which treatments
to oHer patients. The approach is therefore inconsistent. It was
important to do this review to establish if there is evidence for
the eHectiveness of pharmacological interventions in children
with RAP. This review updates a previous review published in
2008 (Huertas-Ceballos 2008a). Companion reviews addressing
the eHectiveness of psychosocial, Huertas-Ceballos 2008b, and
dietary interventions for RAP, Huertas-Ceballos 2009, are also being
updated (Abbott 2017; Newlove-Delgado in press, respectively), so
together they can guide clinicians, patients, and their families in
treatment decisions.
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O B J E C T I V E S
To determine the eHectiveness of pharmacological interventions
for RAP in children of school age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Children aged five to 18 years with RAP or an abdominal pain-
related functional gastrointestinal disorder, as defined by the Rome
III criteria (Rasquin 2006).
Recurrent abdominal pain is defined as at least three episodes
of pain interfering with normal activities within a three-month
period. The Rome III criteria recognises five abdominal pain-related
categories: abdominal migraine, irritable bowel syndrome (IBS),
functional dyspepsia, functional abdominal pain, and functional
abdominal pain syndrome (Rasquin 2006).
Types of interventions
Any pharmacological intervention compared to placebo, no
treatment, waiting list, or standard care.
Types of outcome measures
Primary outcomes• Pain intensity• Pain duration or pain frequency• Improvement in pain
As there is no standard method for measuring pain in this condition,
studies could have used any validated measurement of pain
such as a Likert scale, visual analogue scale, or questionnaire
such as the Abdominal Pain Index (Walker 1997), which exists in
various versions and formats. The trials could also have used 'the
proportion of participants with a significant improvement in pain'
as an outcome, as defined by the trial author.
Secondary outcomes
The following were secondary outcomes, as measured by a
validated tool.
• School performance• Social or psychological functioning• Quality of daily life
Search methods for identification of studies
Electronic searches
We ran the first literature searches in April 2013 and updated them
in April 2014, March 2015, and again in June 2016. We searched the
electronic databases and trial registers listed below.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2016,
Issue 5) in the Cochrane Library and which includes the
Cochrane Developmental, Psychosocial and Learning Problems
Specialised Register (searched 10 June 2016).• Ovid MEDLINE In-Process & Other Non-Indexed Citations and
Ovid MEDLINE (1946 to current; searched 9 June 2016).• Embase Ovid (1974 to current; searched 9 June 2016).• CINAHL Healthcare Databases Advanced Search (Cumulative
Index to Nursing and Allied Health Literature; 1981 to current;
searched 9 June 2016).• PsycINFO Ovid (1806 to current; searched 9 June 2016).• ERIC ProQuest (Educational Resources Information Center; 1966
to current; searched 9 June 2016).• BEI ProQuest (British Education Index; 1975 to current; searched
9 June 2016).• ASSIA ProQuest (Applied Social Sciences Index and Abstracts;
1987 to current; searched 9 June 2016).• AMED Healthcare Databases Advanced Search (Allied and
Complementary Medicine; 1985 to current; searched 9 June
2016).• LILACS (Latin American and Caribbean Literature in Health
Sciences; lilacs.bvsalud.org/en; searched 9 June 2016).• OpenGrey (opengrey.eu; searched 9 June 2016).• ClinicalTrials.gov (clinicaltrials.gov; searched 9 June 2016).• World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP; apps.who.int/trialsearch; searched 9
June 2016).
We revised the search terms from the original Cochrane RAP
reviews (Huertas-Ceballos 2008; Huertas-Ceballos 2009a; Huertas-
Ceballos 2009b); we consequently ran the searches for all available
years. We used RCT filters where appropriate and imposed no
language limits. We translated any non-English language studies
identified so that they could be screened and considered for
inclusion. The search strategies for each database are reported in
Appendix 1.
Searching other resources
We used the Science Citation Index (Web of Science) for forward
citation searching to identify papers in which the included reports
had been cited, and we checked the reference lists of the included
reports to identify any additional studies, including any ongoing
or unpublished work. We also contacted researchers who have
published studies in this field to ask for details of any relevant trials.
Data collection and analysis
Selection of studies
Two review authors (RAA, AB, TVND, or AEM) independently
screened the titles and abstracts of studies identified by the search
for relevance. We obtained the full-text reports of any paper that we
judged to be potentially suitable for inclusion and then identified
studies for inclusion against the Criteria for considering studies for
this review. Any disagreements were resolved through discussion
with a third review author (JTC).
Data extraction and management
Two review authors (RAA, AB, JTC, TVND, or AEM) extracted data
and entered the data into Cochrane's statistical soNware Review
Manager 5 (Review Manager 2014). All review authors used the
same data extraction form. We collected the following data.
Pharmacological interventions for recurrent abdominal pain in childhood (Review)
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• Study characteristics: number of participating children,
inclusion and exclusion criteria, type of intervention and
comparison, intervention characteristics (duration, frequency,
setting), and number of withdrawals.• Participant characteristics: sex, age, and diagnosis (e.g. RAP or a
syndrome defined by the Rome III criteria) (Rasquin 2006).• Outcome measures: measurement of pain and any secondary
outcomes measured.
Assessment of risk of bias in included studies
We considered the following domains when assessing the risk of
bias of included studies:
• selection bias (random sequence generation and allocation
concealment);• performance bias (blinding of participants and personnel);• detection bias (blinding of outcome assessment);• attrition bias (incomplete outcome data);• reporting bias (selective outcome reporting); and• other sources of bias. We assessed all included studies for
other sources of bias that may have altered the estimate of
treatment eHect, such as diHerential loss to follow-up, whether
the data collection tools were valid, whether there was suHicient
power in terms of appropriate sample size, whether baseline
parameters were similar, and whether data analyses were
appropriate.
Two review authors (RAA, AB, JTC, TVND, or AEM) independently
assessed each study. We classified the risk of bias as low, high, or
unclear based on the methods detailed in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a). See Table 1.
We considered a trial as having an overall low risk of bias if most
of the above domains were assessed as at low risk of bias. We
considered a trial as having an overall high risk of bias if several of
the above domains were assessed as at high risk of bias or unclear
risk of bias.
Measures of treatment e:ect
Continuous data
For continuous data (e.g. number of days of pain), we analysed
means and standard deviations (SDs), if these were available or
could be calculated and if there was no clear evidence of skewness
in the distribution, and presented these with 95% confidence
intervals (CIs).
If diHerent scales were used to measure the same clinical outcome,
we combined the standardised mean diHerences (SMDs) across the
studies, and presented these with 95% CIs.
Dichotomous data
For dichotomous data (e.g. pain improved, yes or no), we analysed
data using odds ratios (ORs) and presented these with 95% CIs.
Unit of analysis issues
No methods were used as we did not perform a meta-analysis.
For methods archived for future updates of this review, please see
Appendix 2 and our protocol (Martin 2014a).
Dealing with missing data
We first contacted the original investigators to request any missing
data, but we received no responses. We did not impute any values.
We did not feel it was relevant to carry out a sensitivity analysis,
with and without the missing data, as it was not possible to conduct
a meta-analysis. For methods archived for future updates of this
review, please see Appendix 2 and our protocol (Martin 2014a).
We collected the proportions of participants for whom no outcome
data were obtained and reported them in the assessment of Risk of
bias in included studies. We have also provided this information for
each study in the 'Risk of bias' tables, beneath the Characteristics
of included studies tables. We explored the potential impact of
missing data on the findings of the review in the Discussion section.
Assessment of heterogeneity
We anticipated finding considerable heterogeneity between
included studies. We assessed clinical heterogeneity by examining
the distribution of relevant participant characteristics (e.g. age,
definition of RAP) and study diHerences (e.g. concealment of
randomisation, blinding of outcome assessors, interventions or
outcome measures).
We did not use our prescribed methods for assessing statistical
heterogeneity as we did not perform a meta-analysis. For methods
archived for future updates of this review, please see Appendix 2
and our protocol (Martin 2014a).
Assessment of reporting biases
We examined the report of each study to assess for selective
outcome reporting. We assessed the study as adequate if it met the
following criteria:
• the study protocol was available and all of the study's
prespecified (primary and secondary) outcomes that were of
interest to the review were reported in the prespecified way; or• the study protocol was not available, but it was clear that the
published reports included all expected outcomes, including
those that were prespecified.
Data synthesis
Given the heterogeneity of drug classes and pain measurements
used in the included studies, it was not possible to carry out a
meta-analysis (DerSimonian 1986). We have therefore provided a
narrative description of the results. For methods archived for future
updates of this review, please see Appendix 2 and our protocol
(Martin 2014a).
Summary of findings
We used the GRADE approach to assess the overall quality of the
body of evidence for a specific outcome (Grade Working Group
2013). We used GRADEpro to assess and present the findings in
a 'Summary of findings' table (GRADEpro GDT 2015). There were
11 comparisons in total, as we found 11 classes of drugs in the
studies. We chose to produce a 'Summary of findings' table for
antispasmodic drugs versus placebo (Summary of findings for the
main comparison), as this was the most commonly investigated
drug class in the studies, with a total of four studies. We presented
pain, the primary outcome for this review, in the 'Summary of
Pharmacological interventions for recurrent abdominal pain in childhood (Review)
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findings' table. The measurement of pain varied between studies,
as explained in the Types of outcome measures section.
We judged the studies included for each outcome using five
criteria: risk of bias, indirectness, inconsistency, imprecision,
and publication bias. We used limitations in the design and
implementation to assess the overall risk of bias of included studies
for each outcome; we downgraded an outcome if the majority of
studies had unclear or high risk of bias. We assessed indirectness
if a population, intervention, or outcome was not of direct interest
to the review. Inconsistency was determined by the heterogeneity
of results. If an outcome had a heterogeneity outcome of greater
than 70%, we downgraded the quality of the outcome. Imprecision
was assessed by the number of participants included in an outcome
and by CIs. We downgraded an outcome when only a small number
of participants could be included in the analysis or the analysis
had wide CIs. Finally, we downgraded for publication bias if studies
failed to report outcomes in the published manuscript or if there
was a suspicion that null findings had not been published or
reported (Schünemann 2011, section 12.2.2).
We gave each outcome a quality marking ranging from 'very low' to
'high'.
• High quality: "further research is unlikely to change our estimate
of eHect".• Moderate quality: "further research is likely to have an important
impact on our confidence in the estimate of eHect and may
change the estimate".• Low quality: "further research is very likely to have an important
impact on our confidence in the estimate of eHect and is likely
to change the estimate".
• Very low quality: "we are very uncertain about the
estimate" (Balshem 2011).
Subgroup analysis and investigation of heterogeneity
We used no methods as we did not perform a meta-analysis. For
methods archived for future updates of this review, please see
Appendix 2 and our protocol (Martin 2014a).
Sensitivity analysis
We used no methods as we did not perform a meta-analysis. For
methods archived for future updates of this review, please see
Appendix 2 and our protocol (Martin 2014a).
R E S U L T S
Description of studies
For a full description of the main characteristics of the studies,
including details on participants and setting, intervention aspects,
and outcome measures, see Characteristics of included studies. See
also Characteristics of excluded studies.
Results of the search
For this updated review, we chose to redesign the search strategy
in order to include the recognised terms for diHerent types of RAP,
as defined by the Rome criteria (Rasquin 2006). Consequently, we
ran our searches without date restrictions on each database. The
results of the searching and screening process are shown in the
PRISMA flow chart (Figure 1). We screened a total of 9649 titles and
abstracts, 230 of which we carried forward for further screening at
full-text. We excluded 214 reports and included 16 studies.
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Figure 1.   Study flow diagram.
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Included studies
For details, please see Characteristics of included studies.
We included 16 studies in the review (Asgarshirazi 2015; Bahar 2008;
Collins 2011; Heyland 2012; Karabulut 2013; Karunanayake 2015;
Khoshoo 2006; Kline 2001; Narang 2015; Pourmoghaddas 2014;
Roohafza 2014; Sadeghian 2008; Saps 2009; See 2001; Symon 1995;
Zybach 2016), three of which we included in the previous version of
this review (Kline 2001; See 2001; Symon 1995).
Participants
The number of participants per study ranged from 12, in
Zybach 2016, to 115 (Pourmoghaddas 2014; Roohafza 2014).
Eight studies had more than 50 participants (Asgarshirazi 2015;
Collins 2011; Karabulut 2013; Karunanayake 2015; Narang 2015;
Pourmoghaddas 2014; Roohafza 2014; Saps 2009).
Location
Seven studies were based in the USA (Bahar 2008; Collins 2011;
Khoshoo 2006; Kline 2001; Saps 2009; See 2001; Zybach 2016), four
in Iran (Asgarshirazi 2015; Pourmoghaddas 2014; Roohafza 2014;
Sadeghian 2008), one in the UK (Symon 1995), one in Switzerland
(Heyland 2012), one in Turkey (Karabulut 2013), one in Sri Lanka
(Karunanayake 2015), and one in India (Narang 2015).
Settings
All 16 studies were conducted in hospital paediatric outpatient
clinics.
Study duration
The study duration ranged from two weeks (Collins 2011; Kline
2001; Sadeghian 2008) to four months (Symon 1995). See
Characteristics of included studies for details of each study.
Interventions
Pharmacological interventions, drug classes used; tricyclic
antidepressants (two studies) (Bahar 2008; Saps 2009), antibiotics
(two studies) (Collins 2011; Heyland 2012), antimuscarinics
(one study) (Karabulut 2013), 5-HT4 receptor agonists (one
study) (Khoshoo 2006), antispasmodics (four studies) (Asgarshirazi
2015; Kline 2001; Narang 2015; Pourmoghaddas 2014), selective
serotonin re-uptake inhibitors (one study) (Roohafza 2014),
antihistamines (one study) (Sadeghian 2008), H2 receptor
antagonists (one study) (See 2001), serotonin antagonist (one
study) (Symon 1995), dopamine receptor antagonist (one study)
(Karunanayake 2015), and a hormone (one study) (Zybach 2016).
Study design
Three studies were cross-over trials (See 2001; Symon 1995; Zybach
2016). One study had two intervention arms (Asgarshirazi 2015);
the second intervention is reported in the accompanying review of
dietary interventions (Newlove-Delgado in press). The remaining 12
studies were single-intervention, placebo-controlled trials (Bahar
2008; Collins 2011; Heyland 2012; Karabulut 2013; Karunanayake
2015; Khoshoo 2006; Kline 2001; Narang 2015; Pourmoghaddas
2014; Roohafza 2014; Sadeghian 2008; Saps 2009). All studies were
randomised.
Outcomes
Primary outcome
All 16 included trials measured pain; the method of measurement
varied. Tools included: visual analogue scale (VAS; 0 to 10), mean
pain score and number of days of pain. Some trials used the
parental or child report of adequate pain relief as the outcome
measure.
Secondary outcomes
One study measured school attendance (Narang 2015). One
study measured social and psychological functioning (Roohafza
2014); the authors assessed self rated "depression, anxiety, and
somatization" scores before and aNer treatment. Two studies
measured quality of life (Bahar 2008; Karunanayake 2015). Other
outcomes included: gastrointestinal symptoms scale and global
assessment of well-being. See Characteristics of included studies
for details of outcome measures used in studies.
Excluded studies
We examined 230 full-text reports and excluded 214. Of these, 203
reports were clearly irrelevant. Of the 11 remaining full-text reports,
we excluded four due to ineligible study design (Christensen
1995; Cucchiara 1992; Dehghani 2011; Kaminski 2009), five due
to ineligible populations (Di Nardo 2011; Everitt 2010; Lloyd-Still
1990; Van Outryve 2005; Yadav 1989), and two because of ineligible
comparators (Grillage 1990; Xiao 2013). Please see Characteristics
of excluded studies.
Risk of bias in included studies
For a summary, see Figure 2 and Figure 3.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
 
 
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
Of the 16 included studies, we judged seven to be at low risk
of bias for random sequence generation (Karunanayake 2015;
Khoshoo 2006; Narang 2015; Pourmoghaddas 2014; Roohafza
2014; Sadeghian 2008; Symon 1995), and nine to be at unclear
risk, largely because the authors did not explain their method
of randomisation (Asgarshirazi 2015; Bahar 2008; Collins 2011;
Heyland 2012; Karabulut 2013; Kline 2001; Saps 2009; See 2001;
Zybach 2016).
We rated eight studies at low risk of bias because allocation
concealment had been achieved (Collins 2011; Narang 2015;
Pourmoghaddas 2014; Roohafza 2014; Sadeghian 2008; See 2001;
Symon 1995; Zybach 2016), six studies at unclear risk of bias
because the authors did not mention allocation concealment
(Asgarshirazi 2015; Heyland 2012; Karunanayake 2015; Khoshoo
2006; Kline 2001; Saps 2009), and two studies at high risk of bias
because the methods implied that allocation concealment had not
been achieved (Bahar 2008; Karabulut 2013).
Blinding
We judged 11 studies with clear blinding of participants to be at
low risk of bias (Collins 2011; Heyland 2012; Karunanayake 2015;
Narang 2015; Pourmoghaddas 2014; Roohafza 2014; Sadeghian
2008; Saps 2009; See 2001; Symon 1995; Zybach 2016). We judged
the risk of performance bias as unclear in three studies (Asgarshirazi
2015; Bahar 2008; Kline 2001), and high in two studies where
blinding was not achieved (Karabulut 2013; Khoshoo 2006). These
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judgements were mirrored in the risk of detection bias, as the
primary outcomes were all self or parent reported and therefore
relied on blinding.
Incomplete outcome data
Outcome data were largely complete, and we judged 13 of the
16 included studies to have a low risk of attrition bias (Bahar
2008; Collins 2011; Heyland 2012; Khoshoo 2006; Kline 2001;
Narang 2015; Pourmoghaddas 2014; Roohafza 2014; Sadeghian
2008; Saps 2009; See 2001; Symon 1995; Zybach 2016). We judged
one study to have an unclear risk of attrition bias, as the authors
did not report the numerical outcome data or the number of
participants completing the study, but rather reported results as
a percentage without a total (Karabulut 2013). We judged one
further study to have an unclear risk of attrition bias due to
insuHicient information in the conference abstract and no further
information from personal communication with the study authors
(Karunanayake 2015). We judged one study to be at a high risk of
attrition bias, as there were diHerential losses to follow-up between
the groups (Asgarshirazi 2015).
Selective reporting
We considered the risk of reporting bias to be unclear in two
studies (Collins 2011; Khoshoo 2006), and high in three studies
(Bahar 2008; Kline 2001; Narang 2015), because the authors did
not report results for all the outcomes mentioned in the methods
section. We rated the risk of reporting bias as low in 11 studies
(Asgarshirazi 2015; Heyland 2012; Karabulut 2013; Karunanayake
2015; Pourmoghaddas 2014; Roohafza 2014; Sadeghian 2008; Saps
2009; See 2001; Symon 1995; Zybach 2016).
Other potential sources of bias
We judged the risk of other potential sources of bias as high in
10 studies (Asgarshirazi 2015; Bahar 2008; Collins 2011; Karabulut
2013; Narang 2015; Sadeghian 2008; Saps 2009; See 2001; Symon
1995; Zybach 2016), and unclear in four studies (Heyland 2012;
Karunanayake 2015; Khoshoo 2006; Kline 2001), due to lack of
details on baseline characteristics, lack of power calculations,
lack of details on how outcomes were measured, and insuHicient
washout periods in cross-over trials. We rated two studies at
low risk of other potential sources of bias (Pourmoghaddas 2014;
Roohafza 2014).
For each domain above, where there was insuHicient information
to make a judgement of high or low risk of bias, we wrote to all trial
authors for clarification (Abbott 2014a [pers comm]; Abbott 2014b
[pers comm]; Martin 2014b [pers comm]; Martin 2014c [pers comm];
Martin 2016a [pers comm]; Martin 2016b [pers comm]; Martin
2016c [pers comm]; Martin 2016d [pers comm]; Martin 2016e [pers
comm]; Martin 2016f [pers comm]; Martin 2016g [pers comm]). As
we received limited response, we assigned ratings of unclear risk of
bias for these studies in these domains.
E:ects of interventions
See: Summary of findings for the main comparison
Antispasmodics compared to placebo for recurrent abdominal pain
Comparison 1. Tricyclic antidepressants compared to placebo
Two studies, Bahar 2008 and Saps 2009, evaluated amitriptyline
compared to placebo in 123 children with functional
gastrointestinal disorders as defined by the Rome II criteria
(Rasquin-Weber 1999).
Bahar 2008 assessed multiple outcomes measuring pain (using a
pain-rating scale and VAS), quality of life, and IBS symptoms for up
to 13 weeks. The quality of life tool had been validated in adults
(Patrick 1997). The authors reported no significant diHerence in
pain between the two groups, but provided no data to support this.
The mean quality of life scores were 109.4 and 127.5 at baseline
for the intervention and control groups, respectively. At 13 weeks'
follow-up, they were 126.2 and 129.8 for the intervention and
control groups, respectively. The authors suggested that a higher
proportion of participants in the intervention group showed a 15%
increase in quality of life at 13 weeks compared to the control group
(P = 0.002). The clinical significance of this is unclear. Of note, the
two groups had a 14% diHerence of mean quality of life scores
at baseline. This may have been a post-hoc analysis, as it is not
mentioned in the methods of the study. The study authors did
not provide the standard deviations for these data. We wrote to
the study authors to request further information but received no
response (Abbott 2014b [pers comm]).
Saps 2009 used author-defined outcomes to evaluate improvement
in pain from amitriptyline compared to placebo at four weeks'
follow-up. They found no diHerence between the intervention and
control groups when assessing the self reported outcomes of "how
well did the medication relieve your pain" and "overall how do you
feel your problem is". Out of the 46 children in the amitriptyline
group, 23 experienced an improvement in pain, compared to 22 out
of 44 in the control group (OR 1.05, 95% CI 0.45 to 2.45).
We were unable to perform a meta-analysis due to the use of
diHerent outcome measures and lack of numerical data. The GRADE
quality rating for this outcome was very low, due to the small
number of studies with methodological flaws.
Comparison 2. Antibiotics compared to placebo
Two studies, Collins 2011 and Heyland 2012, evaluated antibiotics
compared to placebo in 112 children with Rome II criteria for IBS,
functional dyspepsia, functional abdominal pain, or abdominal
migraine (Rasquin-Weber 1999), and RAP (Apley 1958).
Collins 2011 assessed the eHectiveness of rifaximin compared to
placebo. The authors used 10 self reported outcomes on a VAS and
a pain questionnaire to evaluate improvement in pain. The 10 self
reported outcomes included: incomplete evacuation, abdominal
pain, diarrhoea, constipation, urgency to pass stool, passage of
mucus, straining, and faecal soiling. The authors stated that there
were no diHerences between the intervention and control groups
for any of the outcomes. The authors did not present their data to
support this conclusion. We contacted the authors but received no
response (Abbott 2014a [pers comm]).
Heyland 2012 also reported the use of antibiotics to treat RAP.
They compared co-trimoxazole to placebo on the mean pain index.
This was a 10-point VAS measuring pain severity for each group.
The mean pain index changed from 6.9 pre-treatment to 4.1 post-
treatment in the intervention group, a mean change of -2.9. In
the placebo group, the mean pain index changed from 7.4 pre-
treatment to 3.0 post-treatment, a mean change of -4.4. The
authors found no diHerence in scores on the mean change of
pain index between the two groups. No raw data were given. We
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contacted the authors but received no response (Martin 2016c [pers
comm]).
We were unable to perform a meta-analysis due to lack of
numerical data. These papers oHer no evidence of the eHectiveness
of antibiotics to treat functional gastrointestinal disorders. The
GRADE quality rating for this outcome was very low, due to lack of
reliable outcome data to assess precision of treatment eHect, and
small and single studies for any drug intervention.
Comparison 3. Antimuscarinic drugs compared to usual care
Karabulut 2013 compared trimebutine to usual care in 78 children
with IBS as defined by Rome III criteria (Rasquin 2006). The authors
reported a self defined outcome of pain improvement, "adequate
relief", as assessed by the parents. There was an improvement
in 37 out of 39 children treated with trimebutine and in eight
out of 39 children treated with usual care (P < 0.0001; OR 71.7,
95% CI 14.2 to 362.7). However, it is important to note that the
intervention was not blinded and that the outcome measure was
parental assessment, therefore performance and detection bias
alone could explain the results. Consequently, the GRADE quality
rating was very low, and the results should be interpreted with
caution.
Comparison 4. 5-HT4 agonists compared to usual care
Khoshoo 2006 compared tegaserod with usual care in 48 children
with constipation-predominant IBS. The authors reported 14 out
of 21 children with good pain reduction in the treatment group
compared with 5 out of 27 children in the control group (P
< 0.05 (exact P value not reported in paper); OR 8.8, 95% CI
2.3 to 33.2). This suggests that tegaserod may be eHective in
relieving abdominal pain in constipation-predominant IBS. Due
to the small number of children participating in the study and
the risk of performance and detection bias, this result should be
interpreted with caution. Importantly, it is not clear if this was a
post-hoc analysis. The GRADE quality rating for this comparison
was therefore very low.
Comparison 5. Antispasmodics compared to placebo
Four trials compared antispasmodics to placebo in 377 children
with functional abdominal pain (Asgarshirazi 2015; Kline 2001;
Narang 2015; Pourmoghaddas 2014). For a summary of
antispasmodics, see Summary of findings for the main comparison.
Asgarshirazi 2015 compared peppermint oil, placebo and a
synbiotic Lactol (containing a probiotic and fructo-oligosaccharide)
in a three-arm RCT. One hundred and twenty children with
functional gastrointestinal disorders based on Rome III criteria
were included in the study, but those with abdominal migraine
were excluded. Changes in severity, duration, and frequency of pain
and any adverse eHects were reported at four weeks. The results for
the synbiotic intervention are reported in an accompanying dietary
review (Newlove-Delgado in press). Thirty-four children completed
the study and were analysed in the peppermint oil intervention
group and 25 in the placebo group. The authors reported the
intervention group compared to placebo: mean diHerence (MD)
in pain duration -25.4 minutes/day (95% CI -35.5 to -15.3), MD in
frequency of pain -1.4 episodes/week (95% CI -2.0 to -0.8), and MD
in severity of pain -1.1 on a numerical rating scale (95% CI -1.8 to
-0.4). Notably, this trial was at risk of bias from incomplete outcome
data and diHerential loss of children between groups (38% drop
out in the placebo group and 15% in the intervention group). The
placebo was diHerent in preparation and dose timing compared to
the intervention drug.
Kline 2001 also compared peppermint oil capsules with placebo
in 42 children with IBS as defined by the Rome criteria (Rasquin-
Weber 1999). The authors reported that, at two weeks, 15 out
of 21 children in the peppermint group had a clinician-judged
improvement in pain compared to 9 out of 21 in the placebo group
(OR 3.33, 95% CI 0.93 to 12.01). The authors reported the 15-item
Gastrointestinal Symptom Rating Scale (Svedulend 1988), which
measures frequency, duration, and impact on daily life, as showing
no diHerence between groups, but do not provide the data in the
study. We contacted the trial authors but received no response
(Martin 2016f [pers comm]). The authors reported that daily diaries
completed by children showed significantly lower mean pain
severity in the peppermint oil group. The authors provided neither
data nor explanation of how the analysis of the daily diaries was
carried out, although the P value for this comparison was reported
to be less than 0.03. No side eHects were reported in either group.
This study therefore provides insuHicient evidence to support the
use of peppermint oil in the treatment of RAP.
Narang 2015 compared drotaverine to placebo in a RCT with 132
children with RAP as defined by Apley (Apley 1958). They assessed
children's pain severity and frequency, school attendance, and
parental judgement of well-being (Likert scale) aNer four weeks.
The authors provided no results for pain severity, only pain
frequency, reporting the mean number of episodes of pain in four
weeks and number of pain-free days in four weeks. They found a
mean of 10.3 (SD = 14) episodes of pain in the 64 children receiving
drotaverine and a mean of 21.6 episodes (SD = 32.4) in the 60
children receiving placebo. The MD between the groups in episodes
of pain was 11.3 (95% CI 2.4 to 20.1). The mean number of pain-free
days was 17.4 (SD = 8.2) in the intervention group and 15.6 (SD =
8.7) in the placebo group; MD 1.8, 95% CI -1.2 to 4.8. The authors
reported the mean number of school days missed as 0.24 (SD = 0.85)
in the drotaverine group and 0.71 (SD = 1.59) in the placebo group.
The MD between these two groups was 0.46 (95% CI 0.01 to 0.91).
Pourmoghaddas 2014 randomised 115 children to mebeverine
versus placebo, and found no eHectiveness of mebeverine in
treating functional abdominal pain in children. Self reported
treatment response rates in the mebeverine and placebo groups
were 40.6% and 30.3%, respectively at four weeks' postintervention
(P = 0.469; OR 1.6, 95% CI 0.7 to 3.4) and 54.2% and 41.0%,
respectively at 12 weeks' postintervention (P = 0.416; OR 1.7, 95%
CI 0.8 to 3.6). This was an intention-to-treat analysis; the authors
used last observed carried forward to substitute for missing data.
The authors found no diHerence between the groups in scores on
the physician-rated change of the Clinical Global Improvement-
Severity scale, at four or 12 weeks' postintervention (NIMH 1985).
A meta-analysis of studies evaluating antispasmodic drugs was not
possible due to the heterogeneity of the interventions and variation
in outcome measures. The overall GRADE quality rating for evidence
evaluating this comparison was very low.
Comparison 6. Selective serotonin re-uptake inhibitors (SSRIs)
compared to placebo
Roohafza 2014 compared citalopram and placebo in 115 children
with functional abdominal pain as defined by Rome III criteria
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(Rasquin 2006). The authors found no diHerence in treatment
response rate between the groups at four weeks' postintervention
(40.6% citalopram, 30.3% placebo; P = 0.169; OR 1.6, 95% CI
0.7 to 3.4) or at 12 weeks' postintervention (52.5% citalopram,
41.0% placebo; P = 0.148; OR 1.6, 95% CI 0.8 to 3.3). This was an
intention-to-treat analysis. The authors used last observed carried
forward to substitute for missing data. In addition, there were no
diHerences between the two groups on scores for the secondary
outcomes of self assessed change in severity of depression, as
assessed using the Children's Depression Inventory (Kovacs 1985);
anxiety, as assessed using the Revised Children's Manifest Anxiety
Scale (Reynolds 1979); or somatization, as assessed using the
Children's Somatization Inventory (Walker 2009), at four or 12
weeks' postintervention. The citalopram group experienced more
drowsiness (37.2% citalopram, 16.2% placebo; P = 0.025) and dry
mouth (44.1% citalopram, 23.2% placebo; P = 0.034) compared to
the placebo group. The overall GRADE quality rating for evidence
evaluating this comparison was very low.
Comparison 7. Antihistamines compared to placebo
Sadeghian 2008 randomised 29 children with functional abdominal
pain as defined by Rome II criteria to cyproheptadine or placebo
(Rasquin-Weber 1999). They reassessed the outcome measures
of pain intensity, pain frequency, and global self judgement of
improvement in symptoms at two weeks. Pain intensity and pain
frequency improved in 9 out of 15 children in the treatment group
and 2 out of 14 children in the placebo group (OR 9.0, 95% CI
1.46 to 55.48). While this result suggests eHectiveness, it should
be interpreted with caution due to the very low GRADE quality
rating of the evidence. The study was at risk of bias from the small
sample size (imprecision of treatment eHect), used non-validated
measurement tools, and the findings have not been reproduced in
other studies.
Comparison 8. H2 receptor antagonists compared to placebo
One study, See 2001, compared famotidine versus placebo in a
randomised cross-over trial of 25 children with RAP, as defined
by Apley 1958. The authors provided results from the first period
of the trial during which 12 children received famotidine and 13
children received placebo. They reported that 8 out of 12 children
receiving famotidine in the first period improved compared to 2 out
of 13 children receiving placebo in the first period (OR 11.0, 95%
CI 1.6 to 75.5). They also reported scores on an "abdominal pain
score" (APS), which included three components: pain frequency,
pain severity, and a peptic index score, which evaluates a number
of symptoms, including nausea, vomiting, and nocturnal waking.
This appears not to be a validated tool used in other studies. The
authors reported no statistically significant diHerence in scores
between famotidine and placebo, considering all the data from
both periods. They reported finding an improvement in APS on
famotidine (mean 3.37 (SD ± 3.53)) and on placebo (mean 1.66
(SD ± 2.7)). The MD in improvement on APS is 1.71. We were not
able to provide confidence intervals around this diHerence due to
insuHicient data from the study authors. This is a cross-over trial,
and we did not impute values for the correlation coeHicient. The
authors of the previous review were unsuccessful in contacting the
trial authors (Huertas-Ceballos 2008a). The GRADE quality rating
was very low due to the lack of primary data to confirm findings, no
washout period between cross-over of interventions, and the use
of an invalidated tool.
Comparison 9. Serotonin antagonists compared to placebo
Symon 1995 reported the eHects of pizotifen versus placebo in a
restricted subgroup of 16 children with RAP. Although the children
satisfied the standard definition of RAP (Apley 1958), they also
had to report associated facial pallor, and either one first-degree
relative or two second-degree relatives with a history of migraine
or throbbing headache to be included in the study. This was a
cross-over study comparing the MD in the number of days on
which children reported abdominal pain while taking pizotifen
and placebo. The children reported a MD of 8.21 (95% CI 2.93 to
13.48) fewer days of pain while taking the intervention drug. The
authors also reported the MD on the "Index of Severity", which
was -16.21 (95% CI -26.51 to -5.90), and the MD on the "Index of
Misery", which was -56.07 (95% CI -94.07 to -18.07). These appear
not to be validated tools, but were judged by the trial authors
to measure improvement. The study authors reported P values
of 0.005 and 0.007 for these two comparisons, respectively. The
authors reported that the trial was stopped early as a result of
an interim analysis conducted when their initial supplies of drug
preparations reached their expiry dates. They did not provide
details of the size of the sample they had originally planned to
include in the study. These findings have not been replicated in
other studies. The GRADE rating was very low for this comparison.
Comparison 10. Dopamine receptor antagonist compared to
placebo
Karunanayake 2015 compared domperidone to placebo in 89
children aged five to 12 years with abdominal pain-predominant
functional gastrointestinal disorders as defined by Rome III criteria
(Rasquin 2006). Two primary outcomes were specified: cure and
improvement. Cure was abdominal pain less than 25 mm on the
VAS and no impact on daily activity. Improvement was pain relief
and sense of improvement recorded on the Global Assessment
Scale. No further information on how these primary outcomes
were defined, when they were measured, or who assessed them
was provided. The study is available as a conference abstract,
and despite having written to the authors twice (Martin 2016a
[pers comm]; Martin 2016d [pers comm]), we have no further
published or unpublished information. The authors state that
there was no diHerence in "cure" between the two groups, but
provided no data to support this. They state that 37 out of 47
(78.7%) of the children treated with domperidone had "significant
improvement" and 25 out of 42 (59.5%) in the placebo group
had "significant improvement". This gives an OR for improvement
of 2.52 (95% CI 0.99 to 6.39). Due to the lack of information
about this outcome measurement and the limited possible 'Risk
of bias' assessment, this result should be interpreted with
caution. Regarding secondary outcomes, the domperidone group
reported a significant reduction in abdominal pain severity (70.84%
versus 48.18%) and improvement on the motility index (29.3%
versus 8.6%) aNer intervention. No such diHerence was seen in
improvement of quality of life and family impact. It was also unclear
how these secondary outcomes were defined, measured, or who
assessed them. The GRADE rating was very low for this comparison.
Comparison 11. Hormone treatment compared to placebo
Zybach 2016 reported the therapeutic eHect of melatonin
compared to placebo in 12 children aged 11 to 16 years with
functional abdominal pain as defined by Rome III criteria (Rasquin
2006). This was a cross-over study with no washout period. No
power calculation was performed, but due to the low number of
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children, the study may have been underpowered. The authors
found no diHerence in pain response reported by those treated with
melatonin compared to placebo: OR 0.71 (95% CI 0.14 to 3.58). The
authors also reported no change in mean sleep duration: melatonin
group 9.9 (SD ± 3.53) hours; placebo group 9.41 (SD ± 2.7) hours. The
GRADE rating for this comparison was very low.
D I S C U S S I O N
Summary of main results
Recurrent abdominal pain is an extremely common condition
in childhood, and survey data in the USA suggest that many
paediatricians use drug treatment for RAP (Edwards 1994). The
most striking result of this review is the paucity of good-quality,
placebo-controlled trials for all of the drugs that have been
recommended for use in children with RAP.
In 2006, the paediatric Rome III criteria were devised to classify
paediatric functional gastrointestinal disorders (Rasquin 2006).
Diagnoses included within this classification comprised five
categories defined on the basis of symptom profiles: IBS, functional
dyspepsia, functional abdominal pain, abdominal migraine, and
functional abdominal pain syndrome. The consistent symptom in
each of these profiles is unexplained abdominal pain, which, prior
to the development of this classification, was the complaint used to
identify patients. It remains unclear the extent to which separating
children into these subgroups defines patients who have diHerent
psychological or pathophysiological mechanisms underlying their
symptoms or predicting their treatment response.
The studies with positive results are either small, single studies that
have not been replicated or are larger studies with methodological
flaws. Therefore, there is insuHicient evidence to recommend any
drug treatment.
There was no evidence from Bahar 2008 or Saps 2009 to suggest
that amitriptyline is eHective in treating RAP. Similarly, there was no
evidence that antibiotics have a role in the treatment of RAP (Collins
2011; Heyland 2012). A single study reported that trimebutine
(an antimuscarinic drug) was extremely eHective in treating RAP
(Karabulut 2013), but this was based on reports of symptoms by
parents who were aware of whether their children were either
receiving active treatment or not. A single, small study with a high
risk of bias evaluated tegaserod (a 5-HT4 agonist) (Khoshoo 2006).
The findings of this study suggest that tegaserod may be eHective,
but further evidence is required before it can be recommended.
We found two trials of peppermint oil: one trial showed no clear
eHicacy, but the small numbers may mean it was underpowered
(Kline 2001), and the second trial had key methodological flaws
requiring that it be interpreted with caution (Asgarshirazi 2015).
There is no current evidence to recommend peppermint oil. Narang
2015 suggested benefit from drotaverine in some of the outcomes
measured; others were either unreported or the children received
no benefit from the intervention. Pourmoghaddas 2014 found
no eHectiveness of mebeverine in treating functional abdominal
pain in children. Similarly, Roohafza 2014 compared citalopram
and placebo and found no diHerence in treatment response rate
between the groups. Sadeghian 2008 and See 2001 suggested
that antihistamines and H2 receptor antagonists respectively
may be eHective in treating RAP. However, these results should
be interpreted with caution due to risk of bias in the studies,
small sample numbers, and therefore imprecision of estimates.
In addition, the results of these single studies have not been
reproduced. Symon 1995 reported the eHects of pizotifen versus
placebo in a subgroup of children with RAP fulfilling the definition
of abdominal migraine. In the 14 children studied, the mean
number of days of pain was less in the pizotifen group. The results
of this small study, which was stopped early as this interim analysis
was conducted when the drug supply had expired, has not been
replicated in the last 20 years. Karunanayake 2015 published in
abstract form a study of domperidone versus placebo; there was
insuHicient information on the outcomes measured and the quality
of the study to conclude if domperidone may be eHective in treating
RAP. Zybach 2016 investigated melatonin compared to placebo in a
small number of children in a cross-over trial and found no eHicacy.
For a summary of these results, please see Summary of findings for
the main comparison.
Overall completeness and applicability of evidence
This review highlights some issues concerning the overall
completeness and applicability of the evidence of benefits
and harms of pharmacological interventions for children and
adolescents with RAP: the lack of trials conducted in specific
subgroups of RAP as defined by the Rome III criteria (Rasquin
2006); the lack of trials assessing the same class of drug; and the
lack of sustained intervention and follow-up beyond the period of
intervention.
The majority of studies included children within the broad
diagnosis of RAP, which meant that children could be presenting
with a variety of RAP classifications such as IBS, functional
abdominal pain, or functional dyspepsia. This meant that it was
not possible to investigate whether particular classes of drugs
benefited particular subgroups of RAP more than other subgroups.
Lastly, most of the interventions were relatively short in duration
(two to six weeks), and very few had medium- or long-term follow-
up, which limits the ability to assess whether any benefits are
sustained in the long term.
Quality of the evidence
The overall quality of this evidence was low.
Potential biases in the review process
The present systematic review has many strengths. We developed
a protocol for this review according to guidance provided in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b). We published our protocol before we embarked on the
review itself (Martin 2014a). We conducted extensive searches of
relevant databases and checked forward and backward citations of
all included studies. We also contacted authors of included studies
for additional data when the presented data were insuHicient
or data were missing, to maximise our ability to pool data on
comparable outcomes within comparable intervention types. Two
review authors, working independently, selected trials for inclusion
and extracted data. Disagreements were resolved by discussion
between team members. We assessed the risk of bias in all
trials according to the recommendations provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We did not include studies that had a mix of children, adolescents,
and young adults when it was not possible to separate the data for
children younger than 18 years of age. Likewise, we did not include
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studies that did not specify recruiting children or adolescents, and
which presented mean ages of the population sample exceeding 20
years of age. Both these issues raise the possibility of bias in our
review process, as we did not write to these authors asking whether
or not they collected data for children younger than 18 years of age.
However, we believe this potential bias is not likely to have changed
our conclusions.
Agreements and disagreements with other studies or
reviews
The previous version of this review, Huertas-Ceballos 2008a,
included only three studies (Kline 2001; See 2001; Symon 1995).
This update includes 16 studies and reached a similar conclusion:
there is no evidence to support the use of drugs to treat RAP or
functional gastrointestinal disorders in children. Another Cochrane
review evaluating the eHectiveness of antidepressants in pain-
related functional abdominal disorders in children also agrees with
this conclusion (Kaminski 2009).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, this review provides only extremely weak evidence for
the eHicacy of some pharmacological agents in children with RAP.
The lack of clear evidence of eHectiveness for any drug suggests
that there is little reason for their use outside of well-conducted
clinical trials. Clinicians may choose to prescribe drugs to children
whose symptoms are severe and who have not responded to simple
management. However, when using drugs as a 'therapeutic trial',
clinicians need to be aware that RAP is a fluctuating condition and
any 'response' may reflect the natural history of the condition or a
placebo eHect, rather than drug eHicacy.
Implications for research
The pathogenesis of RAP in children remains unclear (Hyams 1998).
There is an obvious need for further studies to be conducted to
elucidate this aetiology. It may be that the complaint of pain is
a unifying manifestation for a wide variety of causal pathways
and triggers relating to psychological and physical processes.
It is unlikely that RAP is a single disease entity. Further trials
are therefore needed not only to guide the management of
children with RAP, but also to validate the usefulness of suggested
classifications (Rasquin 2006).
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Methods Design: 3-arm randomised placebo-controlled trial
Duration: 4 weeks
Participants Country: Iran
Setting: paediatric gastroenterology outpatient clinic
Sample size: 120 children (40 synbiotic, 40 peppermint oil, 40 control)
Gender: peppermint oil group: 15 girls and 19 boys; control group: 17 girls and 8 boys
Mean age (SD): 7.06 (+/-2.38) years peppermint oil group; 7.42(+/-2.49) years control group
Dropouts/withdrawals: 32 withdrawals, number analysed = 88
Diagnosis: functional gastrointestinal disorders using Rome III (Rasquin 2006)
Interventions Intervention: Colpermin (peppermint oil 187 mg capsule), 1 capsule if < 45 kg and 2 capsules if > 45
kg), 3 x day, 30 minutes before each meal
Control: folic acid tablet (1 mg), 1 tablet, once daily, 30 minutes before breakfast or lunch
3rd arm: synbiotic Lactol tablet (containing a probiotic and fructo-oligosaccharide) (see dietary review
Newlove-Delgado in press for this comparison)
Outcomes • Pain severity (using rating scale 0 to 10)• Pain duration: minutes per day• Pain frequency: episodes per week
Notes Study dates: September 2012 to August 2014
Funding: not stated
Conflicts of interest: not reported
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised in blocks, but give no de-
tails of the method of random sequence generation.
Allocation concealment
(selection bias)
Unclear risk The authors do not acknowledge this concept in the paper. In personal corre-
spondence, the authors reported that it was not important (Asgarshirazi 2016
[pers comm]). Therefore, on balance, we judged this to be at unclear of risk of
bias.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The study authors do not specifically state that participants were blinded,
although they do say that the nurse that carried out the questionnaire was
blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk As above, note also that the placebo regimen of folic acid tablets was once dai-
ly and the intervention regimen of peppermint oil capsules was 3 times daily.
These different preparations and timings could have introduced bias, as the
outcome was self reported and therefore influenced by the participants expe-
rience.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 32 participants were excluded or withdrawn after randomisation. Attrition
differed between the groups, 15% of the intervention group and 38% of the
placebo group.
Selective reporting (re-
porting bias)
Low risk All outcomes in the methods appear to be reported.
Other bias High risk No power calculation. The intervention and placebo groups differed at base-
line: duration of pain in the intervention group was 67.05 mean minutes/day
(SD +/- 36.97) and the placebo group was 53.4 mean minutes/day (SD +/-
16.81).
Asgarshirazi 2015  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 13 weeks
Participants Country: USA
Setting: private paediatric gastroenterology outpatient clinic
Sample size: 33 children (intervention 16, control 16)
Gender: 9 boys, 24 girls
Mean age: intervention 15.3 years; control 14.2 years. Overall range 12 to 18 years
Dropouts/withdrawals: 0
Diagnosis: meet the Rome II criteria for IBS (Rasquin-Weber 1999)
Interventions Intervention: 7-week course of oral amitriptyline (10 mg if 30 to 50 kg, 20 mg if 50 to 80 kg, 30 mg if > 80
kg), taken at night
Control: placebo
Outcomes • Quality of life• Pain intensity and frequency
Bahar 2008 
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• IBS symptom checklist - validated in adults (Patrick 1997)• Pain rating scale
Timing of outcome assessment: measured at 6, 10, and 13 weeks
Notes Study dates: 2002 to 2005
Funding: James and Diane Brooks Medical Research Foundation and AstraZeneca
Conflicts of interest: not mentioned
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but give no details of the
method of randomisation.
Allocation concealment
(selection bias)
High risk The authors do not mention this concept in the paper.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk This is mentioned in the title but no details are provided.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The outcome measurement is self assessed, therefore if the participant is
blinded so too is the outcome assessment. No details of the blinding are pro-
vided.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The authors state that no participants dropped out after starting treatment.
Selective reporting (re-
porting bias)
High risk The authors state in their methods that improvement in overall quality of life
score is the primary outcome but provide no details of a threshold regarded as
improvement. At baseline, the quality of life score for the intervention group
was 14% lower than that of the placebo group, 109.4 and 127.5 respectively. In
the analysis, at 10 and 13 weeks' follow-up, the quality of life score was 128.0
and 126.2 respectively for the intervention group and 129.4 and 129.8 respec-
tively for the placebo group. The authors conclude that the number of partic-
ipants with a greater than 15% improvement is significantly higher in the in-
tervention group; this could be wholly explained by the difference at baseline.
This may also be a post-hoc analysis, as the authors do not mention this in the
methods. The authors also selected some symptoms from the functional ab-
dominal pain score and reported these as improved, e.g. periumbilical and
right lower quadrant pain, but abdominal pain in other areas showed no im-
provement with the intervention.
Other bias High risk There is no power calculation. Baseline data of the participants are not pro-
vided. Compliance with the intervention is mentioned. There is no raw data
to verify the statistics quoted. We wrote to the authors to request these data
but received no response. The validity of the outcome assessment tool or clin-
ical relevance of the reported outcomes are not mentioned. For example, is a
15% improvement in the quality of life scale at 13 weeks, but not at 10 weeks,
clinically important? The number of participants is small and the follow-up is
short.
Bahar 2008  (Continued)
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Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 2 weeks
Participants Country: USA
Setting: paediatric gastroenterology clinic at a children's hospital and an outreach clinic
Sample size: 75 children (intervention 49, control 26)
Gender: intervention 15 boys, 34 girls; control 6 boys, 20 girls
Mean age: intervention 12.5 years (SD 3.01); control 13.16 years (SD 2.97)
Dropouts/withdrawals: 5: intervention 3, control 2
Diagnosis: Rome II criteria for IBS, functional dyspepsia, functional abdominal pain, or abdominal mi-
graine (Rasquin-Weber 1999)
Interventions Intervention: 550 mg rifaximin 3 times daily for 10 days
Control: placebo
Outcomes • 10 symptoms rated on a visual analogue scale (0 to 10)
Timing of outcome assessment: 2 weeks
Notes 10 symptoms = bloating, excess gas, incomplete evacuation, abdominal pain, diarrhoea, constipation,
urgency, passage of mucus, straining, faecal soiling
Study dates: 2010
Funding: the study was funded by Salix Pharmaceuticals, Saban Research Institute, and Children's
Hospital of Los Angeles
Conflicts of interest: none reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but provide no details of
the method of randomisation.
Allocation concealment
(selection bias)
Low risk The authors state that randomisation was performed by personnel not associ-
ated with the study and that the study personnel were blinded. This implies al-
location concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The authors state that the participants and personnel were blinded and that a
matching placebo was used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcomes were measured by self report in a questionnaire and the partici-
pants were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The authors state that outcome assessment is missing for 5 participants, 3
from the intervention group and 2 from the placebo group. This is a low num-
Collins 2011 
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ber of loss to follow-up and within what would be expected for any study.
There was no differential loss to follow-up between the groups.
Selective reporting (re-
porting bias)
Unclear risk The authors do not present the raw data, i.e. from the 10-point visual analogue
scale of GI symptoms or the overall improvement score. They provide only a
statement that none of the differences were significant. We wrote to the au-
thors to provide the raw data to verify this but received no response. We are
therefore unable to comment on the completeness of the outcome data or the
degree of selective reporting.
Other bias High risk The power calculation is not based on a primary outcome but a laboratory test
- the detection of small intestinal bacteria overgrowth - and is therefore not
valid. The outcome is measured by self report for 10 symptoms, but the valid-
ity of this method is not mentioned. The number of participants is small and
the follow-up is short.
Collins 2011  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 3 weeks
Participants Country: Switzerland
Setting: patients referred to the Department of Paediatric Gastroenterology and Nutrition at the Uni-
versity Children's Hospital, Zurich
Sample size: 37 children (intervention 20, control 17)
Gender: intervention 9 boys, 11 girls; control 7 boys, 10 girls
Mean age: intervention 10.6 years (SD not reported; range not reported); control 11.4 years (SD not re-
ported; range not reported)
Dropouts/withdrawals: 3, not known from which group
Diagnosis: Apley's criteria for RAP (Apley 1958)
Interventions Intervention: 6 mg/kg/day trimethoprim and 30 mg/kg/day sulfamethoxazole in 2 divided doses for 7
days
Control: placebo twice daily for 7 days
Outcomes • Pain Index measured on a visual analogue scale (0 to 10)
Timing of outcome assessment: 2 weeks
Notes Study dates: 2004 to 2008
Funding: not stated in the paper
Conflicts of interest: none reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but provide no details of
the method of randomisation.
Heyland 2012 
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Allocation concealment
(selection bias)
Unclear risk The authors state that randomisation occurred after obtaining written, in-
formed consent, but no additional information is provided. It is therefore un-
clear if there was allocation concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The authors state that the intervention was blinded and a placebo was used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome was self reported and the participants were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The authors state that 3 participants withdrew from the study after inclusion,
but this is unlikely to have significantly altered the results.
Selective reporting (re-
porting bias)
Low risk The primary outcome, Pain Index, was reported for all participants.
Other bias Unclear risk The power calculation is inadequate for this outcome measurement, as it is
based on the breath test findings and not the primary outcome. The baseline
data were presented and showed no imbalances. The number of participants
is small and the follow-up is short. The funding is not stated. The authors re-
port no conflicts of interest.
Heyland 2012  (Continued)
 
 
Methods Design: randomised controlled trial comparing trimebutine with usual care
Duration: 3 weeks
Participants Country: Turkey
Setting: patients attending the general paediatric clinic at the Istanbul University Hospital, Depart-
ment of Paediatric Gastroenterology
Sample size: 78 children (intervention 39, control 39)
Gender: 31 boys, 47 girls. Distribution between groups not given.
Mean age: 9.79 years (SD 3.45). Distribution between groups not given.
Dropouts/withdrawals: 0
Diagnosis: IBS according to the Rome III criteria (Rasquin 2006)
Interventions Intervention: 3 mg/kg/day trimebutine maleate, in 3 divided doses for 3 weeks
Control: usual care
Outcomes • Treatment responders, measured by parental reporting of pain relief• Parents were asked: "Did your child have adequate relief?", responding "yes or no"
Timing of outcome assessment: 3 weeks
Notes Study dates: 2007 to 2008
Karabulut 2013 
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Funding: none
Conflicts of interest: none reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but give no details of the
method of randomisation.
Allocation concealment
(selection bias)
High risk This concept is not mentioned in the paper.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk The participants and study personnel could not have been blinded as there
was no placebo for the control group, who received standard care instead.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The parents were asked to report the outcome, and they would have known
whether the child was taking trimebutine or not.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The authors do not mention this; the raw data is not reported, only the per-
centage of children who improved. We therefore cannot be sure about the loss
to follow-up or how the missing data were handled.
Selective reporting (re-
porting bias)
Low risk The authors state that parental assessment of pain relief was their only out-
come.
Other bias High risk No power calculation was performed and no baseline data are given. Compli-
ance with the intervention is not mentioned. The outcome measurement is
not validated. The number of participants is small and the follow-up is short.
We wrote to the authors to request details regarding the above issues, but re-
ceived no response.
Karabulut 2013  (Continued)
 
 
Methods Design: randomised, placebo-controlled trial
Duration: insufficient detail. The intervention was given for 8 weeks but when the outcomes were mea-
sured is not stated.
Participants Country: Sri Lanka
Setting: outpatient clinic of the university paediatric unit
Sample size: 100 children
Gender: no details about the children at recruitment. In the 89 children that completed the study,
33/47 in the intervention group were girls, and 22/42 in the placebo group were girls.
Mean age: no details. The authors state that the study was designed to recruit children aged 5 to 12
years.
Dropouts/withdrawals: 11
Karunanayake 2015 
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Diagnosis: abdominal pain-predominant functional gastrointestinal diseases fulfilling Rome III criteria
(Rasquin 2006)
Interventions Intervention: domperidone 10  mg, 3 times per day, before meals for 8 weeks
Control: placebo
Outcomes Primary outcomes:
• cure (abdominal pain less than 25  mm on the visual analogue scale and no impact on daily activities);• improvement (pain relief and sense of improvement recorded on Global Assessment Scale).
Secondary outcomes were significant improvement in:
• symptoms, severity was recorded on a validated 100-millimetre visual analogue scale;• gastric motility, assessed using a validated ultrasound method;• quality of life, validated PedsQL Generic Core Scale, version 4.0;• family impact, used PedsQL Family Impact Module.
Timing of outcome assessment: no details
Notes Study dates: no details
Funding: no details
Conflicts of interest: no details
This study is published as a conference abstract. We wrote to the authors and received no further infor-
mation (Martin 2016a [pers comm]; Martin 2016d [pers comm]).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The authors state that computer-generated random numbers were used.
Allocation concealment
(selection bias)
Unclear risk The authors do not mention this.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The authors state that participants were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The authors state that participants and investigators who assessed outcome
measures were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk There is insufficient detail in the published information to assess this.
Selective reporting (re-
porting bias)
Low risk All stated outcomes appear to be reported, although with very limited data.
Other bias Unclear risk There is insufficient detail in the published information to assess this.
Karunanayake 2015  (Continued)
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Methods Design: randomised controlled trial comparing tegaserod plus laxative with laxative alone
Duration: 4 weeks
Participants Country: USA
Setting: medical centre in North America (no further detail given by authors)
Sample size: 48 children (intervention 21, control 27)
Gender: intervention 8 boys, 13 girls; control 11 boys, 16 girls
Mean age: intervention 15.1 years (SD not reported); control 15.37 years (SD not reported)
Dropouts/withdrawals: 0
Diagnosis: constipation-predominant IBS according to Rome II criteria (Rasquin-Weber 1999)
Interventions Intervention: 6 mg tegaserod once daily, oral, on an empty stomach
Control: usual care
Outcomes • Pain measured by visual analogue scale (0 to 10)• Compared mean pain scores and number of children with a good pain reduction, defined by reduction
in score by at least 3 points
Timing of outcome assessment: 4 weeks
Notes Study dates: 2006
Funding: authors state no external financial support was received
Conflicts of interest: none reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Authors state that they used a simple random numbers table to allocate the
treatment groups.
Allocation concealment
(selection bias)
Unclear risk This concept is not mentioned in the paper.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk The control group was not given a placebo, therefore if informed consent was
obtained before inclusion, participants would have been aware of the implica-
tions of their group allocation. The authors state in the discussion that the par-
ticipants were unaware of the different groups. This is concerning. We asked
the authors about this but have not received a reply.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Self reported outcome and therefore not blinded, as explained in performance
bias section, see above
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There appears to be no loss to follow-up.
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Selective reporting (re-
porting bias)
Unclear risk The authors report all the outcomes they stated in the methods, but it is un-
clear from the methods if the definition of a good pain reduction was a pre-
specified outcome; it may be post-hoc analysis.
Other bias Unclear risk The 2 groups are similar at baseline. A power calculation is performed. The eli-
gibility criteria are stated. It is unclear if the pain-rating tool is validated as the
authors state "standard pain rating scale" but give no further details.
Khoshoo 2006  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 2 weeks
Participants Country: USA
Setting: 3 specialist paediatric gastroenterology departments
Sample size: 42 children (intervention 21, control 21)
Gender: 17 boys, 25 girls. Distribution between groups not given.
Mean age: 12 years (range 8 to 17 years). Distribution between groups not given.
Dropouts/withdrawals: 8 (4 from intervention, 4 from control)
Diagnosis: RAP, defined by Apley (Apley 1958)
Interventions Intervention: peppermint oil capsule taken 3 times daily
Control: placebo (arachis oil) capsule
Outcomes • Severity of pain, scale: good to bad (1 to 5)• Change in pain experience, scale: better to worse (1 to 5)• 15-item gastrointestinal symptom rating scale
Timing of outcome assessment: 2 weeks
Notes Study dates: 1999
Funding: Tillotts Pharma AG Switzerland
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state this was a randomised controlled trial, but give no details of
method of randomisation.
Allocation concealment
(selection bias)
Unclear risk The authors did not mention this concept.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk The authors state that the trial was double-blinded and describe that the same
company produced identical intervention and placebo tablets. However, it is
unclear who, if any, of the study personnel were blinded.
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk There is insufficient information in the paper to judge this because the out-
come was based on clinician judgement, parent report, and child report, and
the blinding of all these outcome assessors was not explained.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The authors state that 8 participants withdrew from the study. Reasons for
withdrawal (4 from each group) are clearly stated in the paper and appear not
to be related to treatment effects (2 because of long travel distances to the
clinic; 2 because they were prescribed antibiotics for other reasons; 4 because
they were unable to swallow pills).
Selective reporting (re-
porting bias)
High risk The authors do not report all 5 outcomes mentioned in the methods section.
Other bias Unclear risk There was no power calculation. The eligibility criteria were clearly stated. The
authors state that the groups were similar at baseline, but the details are not
reported. Compliance with the intervention is unclear. The follow-up is short.
Kline 2001  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 4 weeks
Participants Country: India
Setting: tertiary paediatric gastroenterology clinic
Sample size: 132 children (intervention 66, control 66)
Gender: intervention group: 33 boys, 33 girls; control group: 39 boys, 27 girls
Mean age: intervention group: 7.1 (+/- 2.1); control group: 7.4 (+/- 2.6)
Dropouts/withdrawals: 8 (4 from intervention, 4 from control)
Diagnosis: RAP, defined by Apley (Apley 1958)
Interventions Intervention: drotaverine 20 mg (10 mL) liquid 3 x daily for children 4 to 6 years, 40 mg tablet 3 x daily
for children > 6 years
Control: placebo
Both groups could have extra doses if pain was experienced.
Outcomes • Number of episodes of pain in 4 weeks• Number of pain-free days in 4 weeks• Pain severity measured by visual analogue scale and FACES Pain Scale• Number of school days missed in 4 weeks• Parental reporting of their perception of child’s mood, activity, alertness, oral intake, and comfort,
quantified by Likert scale
Timing of outcome assessment: 4 weeks
Notes Study dates: September 2012 to September 2013
Funding: Walter Bushnell Pvt. Ltd. The company supplied a grant and medication for the study. They
had no role in trial design, data collection, or manuscript preparation.
Narang 2015 
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Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Authors state that they used computer-generated block randomisation with
variable block sizes. Stratified for age (4 to 6 and > 6 years).
Allocation concealment
(selection bias)
Low risk Clearly explained by authors
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Clearly explained by authors
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcomes were self and parental reported, therefore participant blinding
meant the outcome assessment was also blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low loss to follow-up: 6 from placebo group and 2 from intervention group
Selective reporting (re-
porting bias)
High risk The outcomes explained in the methods were not all reported, e.g. results for
pain severity are not given. In addition, the outcome 'number of school days
missed in 4 weeks' reported in the results was not mentioned in the methods.
Other bias High risk We were concerned that the method of giving further drug doses if pain is re-
ported could alter the trial outcome reporting, as if the drug works the child
may ask for it more frequently. Therefore, administration of the intervention
and outcome assessment are not independent.
Narang 2015  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial of mebeverine versus placebo
Duration: 12 weeks
Participants Country: Iran
Setting: paediatric gastroenterology outpatient clinic
Sample size: 115 children (intervention 59, control 56)
Gender: 39 boys, 48 girls (children who completed follow-up)
Mean age: 8.5 years (SD 2.1 years) for all children who completed follow-up. Distribution between
treatment groups not given.
Dropouts/withdrawals: intervention 19, control 17
Diagnosis: functional abdominal pain, defined by Rome III criteria (Rasquin 2006)
Interventions Intervention: mebeverine tablets, 135 mg twice daily, for a duration of 4 weeks
Control: placebo
Pourmoghaddas 2014 
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Outcomes Primary outcome: 2-point reduction in FACES Pain Scale (scale 1 to 6) or report of "no pain"
Secondary outcome: physician-rated global severity and improvement using the Clinical Global Im-
pression Severity and Improvement Scales (scale 1 to 7)
Timing of outcome assessment: 12 weeks
Notes Study dates: 2013
Funding: The Isfahan University of Medical Sciences
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation by computer-generated random numbers in 4 blocks
Allocation concealment
(selection bias)
Low risk Authors state allocation was concealed.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Authors state that the doctors, study participants, and study personnel assess-
ing the outcomes were blinded. The drug codes for labelling the bottles were
known only by the pharmacist.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The primary outcome was self reported and therefore blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The loss to follow-up was equal between the 2 groups and was 28/115 (24%) of
randomised participants, shown in flow diagram.
Selective reporting (re-
porting bias)
Low risk All outcomes stated in the methods are reported.
Other bias Low risk 2 groups similar at baseline. Power calculation performed. No conflict of inter-
est. Funded by an academic institution
Pourmoghaddas 2014  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial of citalopram versus placebo
Duration: 12 weeks
Participants Country: Iran
Setting: paediatric gastroenterology outpatient clinic
Sample size: 115 children (intervention 59, control 56)
Gender: intervention group: 11 males, 32 females; control group: 19 males, 24 females (children who
completed follow-up)
Roohafza 2014 
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Mean age: intervention 10.4 years (SD 1.9 years); control 8.5 years (SD 2.2 years) for children who com-
pleted follow-up
Dropouts/withdrawals: 29 children (intervention 16, control 13)
Diagnosis: functional abdominal pain, defined by Rome III criteria (Rasquin 2006)
Interventions Intervention: citalopram tablets 10 mg/day for the 1st week and then 20 mg/day for a total duration of
4 weeks
Control: placebo
Outcomes Primary outcome: 2-point reduction in FACES Pain Scale (scale 1 to 6) or report of "no pain"
Secondary outcome: self rated depression, anxiety, and somatization scores
Timing of outcome assessment: 12 weeks
Notes Study dates: 2013
Funding: The Isfahan University of Medical Sciences
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation by computer-generated random numbers in 4 blocks
Allocation concealment
(selection bias)
Low risk Authors state that allocation was concealed.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Authors state that the doctors, study participants, and study personnel assess-
ing the outcomes were blinded. The drug codes for labelling the bottles were
known only by the pharmacist.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The primary outcome was self reported and therefore blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The loss to follow-up was equal between the 2 groups and was 29/115 (25%) of
randomised participants, shown in flow diagram.
Selective reporting (re-
porting bias)
Low risk All outcomes stated in the methods are reported.
Other bias Low risk 2 groups similar at baseline, except for slight difference in age. Power calcula-
tion performed. No conflict of interest. Funded by an academic institution
Roohafza 2014  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 2 weeks
Sadeghian 2008 
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Participants Country: Iran
Setting: paediatric gastroenterology clinic in Tehran
Sample size: 36 children (included after dropouts 29 children: intervention 15, control 14)
Gender: intervention: 7 boys, 8 girls; control: 5 boys, 9 girls
Mean age: intervention 7.2 years (range 4.5 to 11 years); control 7.7 years (range 5 to 12 years)
Dropouts/withdrawals: 7 (unclear from which group)
Diagnosis: functional abdominal pain, defined by Rome II criteria (Rasquin-Weber 1999)
Interventions Intervention: 0.25 to 0.5 mg/kg/day cyproheptadine in 2 divided doses for 2 weeks
Control: placebo
Outcomes • Pain:* self reported change in abdominal pain frequency (scale 1 to 6);* self reported change in abdominal pain intensity (scale 1 to 6);* self reported impression of improvement (scale 1 to 4);* parental reporting of improvement (satisfactory or not).
Timing of outcome assessment: 2 weeks
Notes Study dates: 2006 to 2007
Funding: none declared
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The authors state that the random allocation was performed using a ran-
domised, quadruple order of A and B.
Allocation concealment
(selection bias)
Low risk The authors explain that the study personnel (research nurse and study physi-
cian) were blinded. This implies allocation concealment, as they did not know
the group to which participants were allocated.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The authors state that the placebo was similar.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The participants were blinded and the outcome was self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 36 participants were randomised. The authors state that 7 participants were
excluded from the final analysis (5 for poor compliance and 2 for incomplete
outcome data). We assume that they came equally from each group, as the in-
cluded numbers of participants were 15 and 14 for the intervention and con-
trol groups, respectively (total 29).
Selective reporting (re-
porting bias)
Low risk The primary outcome was reported.
Sadeghian 2008  (Continued)
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Other bias High risk No power calculation was performed. The outcome was not measured by a
validated tool. The sample size was small and the outcome was measured over
a short time duration. There was no intention-to-treat analysis as the non-
compliant participants were excluded.
Sadeghian 2008  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration: 4 weeks
Participants Country: USA
Setting: 6 paediatric tertiary care hospitals, gastroenterology clinics
Sample size: 90 children (intervention 46, control 44)
Gender: 18 boys, 72 girls. Distribution between groups not given.
Mean age: 12.7 years (range 8 to 17 years)
Dropouts/withdrawals: 7 (3 from intervention group, 4 from control group)
Diagnosis: functional abdominal pain, functional dyspepsia, or IBS, defined by Rome II criteria
(Rasquin-Weber 1999)
Interventions Intervention: 10 mg/day amitriptyline if weight < 35 kg, 20 mg/day amitriptyline if weight > 35 kg, for 4
weeks
Control: placebo
Outcomes • Self reporting of symptoms; children were asked:* "How do you feel your problem is?" Responses were ordinal: better, same, or worse.* "How well did the medication relieve your pain?" Responses were ordinal: excellent, good, fair,
poor, or failed.• These outcomes were then dichotomised into "improved" and "not improved".
Timing of outcome assessment: 4 weeks
Notes Study dates: 2003 to 2006
Funding: grant from American College of Gastroenterology and National Center for Research Re-
sources, National Institutes of Health
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but give no details of the
method of randomisation. The 2 groups look similar at baseline, which sug-
gests the method of randomisation was adequate.
Allocation concealment
(selection bias)
Unclear risk This concept is not mentioned in the paper.
Saps 2009 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The authors state that participants and personnel were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcomes are self and parent reported. The participants were blinded,
and therefore so too was the outcome assessment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 90 participants were included, of whom 83 completed the study, giving a 7.8%
loss to follow-up.
Selective reporting (re-
porting bias)
Low risk All outcomes detailed in the methods were reported.
Other bias High risk The study was under-recruited, as the power calculation stated that 120 par-
ticipants were required, but only 90 were recruited.
Saps 2009  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised, cross-over trial
Duration 6 weeks
Participants Country: USA
Setting: tertiary paediatric hospital clinic at Mount Sinai Medical Center
Sample size: 25 children (cross-over trial so all participants received both interventions)
Gender: 13 boys, 12 girls
Mean age: 10.5 years (range 5.5 to 16.77 years)
Dropouts/withdrawals: 1 participant, excluded after enrolment (as Giardia detected in stool)
Diagnosis: RAP, defined by Apley's criteria (Apley 1958)
Interventions Intervention: 1 mg/kg/day famotidine in 2 divided doses for 3 weeks
Control: placebo
Outcomes • Abdominal pain score (= pain frequency + pain severity + peptic index), self reported• Global assessment = self reporting of response to intervention, "Have you felt better, not better or
worse?"
Timing of outcome assessment: 3 weeks
Notes Study dates: 1998
Funding: none declared
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
See 2001 
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Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but give no details of the
method of randomisation.
Allocation concealment
(selection bias)
Low risk The authors do not mention allocation concealment, but they state that the
study personnel were blinded, only the pharmacy was aware of allocation. We
can therefore assume that at the point of randomisation, the study personnel
did not know the treatment group to which each participant would be allocat-
ed. Outcomes were reported by children and parents, who were blinded to al-
location.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The authors state that both groups were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcomes were self reported, and the participants were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The authors report that of the 26 children originally enrolled, 1 was excluded
due to detection of Giardia. There were no further drops outs and therefore da-
ta were presented for 25 children.
Selective reporting (re-
porting bias)
Low risk All outcomes mentioned in the methods were reported.
Other bias High risk No power calculation, small sample size, baseline data presented and the
groups appear similar. The cross-over trial had no washout period. The cross-
over trial varied according to response to the first treatment, which introduces
bias as it is recognised that RAP is a condition that fluctuates over time. The
raw data are not given, and we received no response from the authors to our
request for this information.
See 2001  (Continued)
 
 
Methods Design: double-blinded, placebo-controlled, randomised trial
Duration 4 months
Participants Country: UK
Setting: hospital general paediatric clinic
Sample size: 14 children
Gender: not stated by authors
Mean age: not reported (range 5 to 13 years)
Dropouts/withdrawals: 2
Diagnosis: abdominal migraine = RAP (Apley 1958), with episodes associated with facial pallor, first-de-
gree relative with headaches
Interventions Intervention: 0.5 mg pizotifen syrup (0.25 mg/5 mL) in 2 divided doses per day. After 1 month the dose
was increased to 0.75 mg/day if there had been no improvement.
Control: placebo
Symon 1995 
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Outcomes • Days of abdominal pain• Index of severity (mild = 1, moderate = 2, severe = 3 attack; totaled for whole period)• Index of misery (= pain severity multiplied by duration)
Timing of outcome assessment: 4 months
Notes Study dates: 1995
Funding: none declared
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk From correspondence with the authors, it was established that the order for
treatment allocation was both blinded and randomised. This was done in the
hospital pharmacy, therefore the study personnel were also blinded.
Allocation concealment
(selection bias)
Low risk From correspondence with the authors, it was established that the randomisa-
tion was performed by the hospital pharmacy, and therefore the study person-
nel were also blinded. This implies there was allocation concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk As explained above
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcomes were reported by parent and child, who were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 2 participants (14%) were excluded, as they had no outcome data.
Selective reporting (re-
porting bias)
Low risk All outcomes mentioned in the methods were reported.
Other bias High risk No baseline data, no power calculation, no washout period for a cross-over tri-
al. The intervention was changed according to response; the authors stated
that the medication was doubled if there was no response. The trial stopped
early due to lack of drug supply.
Symon 1995  (Continued)
 
 
Methods Design: cross-over, placebo-controlled, randomised trial
Duration: 5 weeks
Participants Country: USA
Setting: hospital general paediatric clinic
Sample size: 14 children
Zybach 2016 
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Gender: intervention group (girls 58%; boys 5, girls 7), placebo group (girls 58%; boys 5, girls 7)
Mean age: intervention group: 13.8 (+/- 1.6 years), placebo group: 13.8 (+/- 1.6 years)
Dropouts/withdrawals: 2
Diagnosis: functional abdominal pain, according to Rome III criteria
Interventions Intervention: melatonin 5 mg (20 mL) at night, once daily for 14 days
Control: placebo
Outcomes • Abdominal pain. Global clinical score: participants were interviewed to measure change in abdominal
pain, graded 1 to 5. Grade 3 or above = responders, grade 1 to 2 = non-responders• Sleep. Actigraphy (validated tool for measuring sleep), included time in bed, sleep latency, sleep du-
ration from movements measured by accelerometer
Timing of outcome assessment: 2 weeks
Notes Study dates: not stated by authors, published in 2016
Funding: none declared
Conflicts of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk The authors state that participants were randomised, but give no details of the
method of randomisation.
Allocation concealment
(selection bias)
Low risk Authors clearly state that parents were consented for the trial, and partici-
pant’s assent was obtained prior to study procedures, which implies that allo-
cation concealment was achieved.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Blinding explained, complete for participant and study team, the drug and
placebo were labelled in pharmacy.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The outcome assessment was self reported pain by the child, who was inter-
viewed by the study team. Both the child and study team were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 14 enrolled, 12 completed the study; 14% dropout rate
Selective reporting (re-
porting bias)
Low risk No evidence from the paper of outcomes that were not reported.
Other bias High risk Small study with no power calculation. This is a cross-over study with no
washout period.
Zybach 2016  (Continued)
GI: gastrointestinal
IBS: irritable bowel syndrome
PedsQL: Pediatric Quality of Life Inventory
RAP: recurrent abdominal pain
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Christensen 1995 Ineligible study design
Cucchiara 1992 Ineligible study design
Dehghani 2011 Ineligible study design
Di Nardo 2011 Ineligible population
Everitt 2010 Ineligible population
Grillage 1990 Ineligible comparator
Kaminski 2009 Ineligible study design: literature review
Lloyd-Still 1990 Ineligible population
Van Outryve 2005 Ineligible population
Xiao 2013 Ineligible comparator
Yadav 1989 Ineligible population
 
 
A D D I T I O N A L   T A B L E S
 
'Risk of bias' judgementDomain
Low High Unclear
Selection
bias 
 
Random se-
quence gen-
eration
If the study details any of the following methods: (1) sim-
ple randomisation (such as coin-tossing, throwing dice,
or dealing previously shuffled cards, a list of random
numbers, or computer-generated random numbers);
or (2) restricted randomisation such as blocked, ideal-
ly with varying block sizes or stratified groups, provided
that within-group randomisation is not affected
If the study details no randomi-
sation or an inadequate method
such as alternation, assignment
based on date of birth, case record
number, and date of presenta-
tion. These latter methods may be
referred to as ‘quasi-random’.
If there is insuf-
ficient detail to
judge the risk of
bias
 
Allocation
concealment
If the study details concealed allocation sequence in
sufficient detail to determine that allocations could not
have been foreseen in advance of, or during, enrolment
If the study details a method
where the allocation is known pri-
or to assignment
If there is insuf-
ficient detail to
judge the risk of
bias
Perfor-
mance bias 
 
Table 1.   Assessment of risk of bias in included studies  (Continued)
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Blinding of
participants
and person-
nel
If the study details a method of blinding participants and
personnel. Detail would need to be sufficient to show
that participants and personnel were unable to identify
the therapeutic intervention from the control interven-
tion. 
If the methods detail that the par-
ticipants or study personnel were
not blinded to the study medica-
tion or placebo
If there is insuf-
ficient detail to
judge the risk of
bias
Detection
bias 
 
Blinding of
outcome as-
sessment
If the study details a blinded outcome assessment. This
may only be possible for outcomes that are externally
assessed.
If the outcome assessment is not
blinded. We expect this may be un-
avoidable for self rated outcomes
of unblinded interventions.
If there is insuf-
ficient detail to
judge the risk of
bias
 
Attrition
bias
 
Incomplete
outcome da-
ta
If the study reports attrition and exclusions, including
the numbers in each intervention group (compared with
total randomised participants), reasons for attrition or
exclusions, and any re-inclusions; the impact of missing
data is not believed to have altered the conclusions; and
reasons for the missing data are acceptable
We may judge the risk of attrition
bias to be high due to the amount,
nature, or handling (such as per-
protocol analysis) of incomplete
outcome data.
If there is insuf-
ficient detail to
judge the risk of
bias, e.g. if the
number of chil-
dren randomised
to each treatment
is not reported
Reporting
bias
 
Selective re-
porting
If there is complete reporting of all outcome data. This
will be determined based on comparison of the protocol
and published study, if available.
If the reporting is selective so that
some outcome data are not re-
ported
If there is insuf-
ficient detail to
judge the risk of
bias, e.g. proto-
cols are unavail-
able
Other
sources of
bias
 
Other bias If the study is judged to be at low of risk of other poten-
tial sources of bias, such as no differential loss to fol-
low-up or an adequate washout period in cross-over tri-
als
If there are other sources of bias,
such as differential loss to fol-
low-up or an inadequate washout
period in cross-over trials
If there is insuf-
ficient detail to
judge the risk of
bias
Table 1.   Assessment of risk of bias in included studies  (Continued)
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Appendix 1. Search strategies
Cochrane Central Register of Controlled Studies (CENTRAL; 2016, Issue 5) in the Cochrane Library
Search dates: 19 April 2013 (990 records); 11 April 2014 (1271 records); 26 March 2015 (49 records); 10 June 2016 (81 records).
#1 Pain*:ti,ab
#2 Ache*:ti,ab
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#3 Sore*:ti,ab
#4 Discomfort*:ti,ab
#5 Distress*:ti,ab
#6 Cramp*:ti,ab
#7 Disorder:ti,ab
#8 Disorders:ti,ab
#9 Symptom:ti,ab
#10 Symptoms:ti,ab
#11 Migraine:ti,ab
#12 Migraines:ti,ab
#13 Epilep*:ti,ab
#14 Colic*:ti,ab
#15 Syndrome:ti,ab
#16 Syndromes:ti,ab
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 Stomach*:ti,ab
#19 Abdom*:ti,ab
#20 Intestin*:ti,ab
#21 Viscera*:ti,ab
#22 Tummy:ti,ab
#23 Bowel*:ti,ab
#24 Belly:ti,ab
#25 Gastrointestinal:ti,ab
#26 GI:ti,ab
#27 Gastric:ti,ab
#28 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
#29 #17 and #28
#30 Colonic disease*:ti,ab
#31 Irritable bowel:ti,ab
#32 IBS:ti,ab
#33 Functional dyspepsia:ti,ab
#34 MeSH descriptor: [Irritable Bowel Syndrome] explode all trees
#35 MeSH descriptor: [Colonic Diseases, Functional] explode all trees
#36 MeSH descriptor: [Abdominal Pain] explode all trees
#37 MeSH descriptor: [Dyspepsia] explode all trees
#38 MeSH descriptor: [Colic] explode all trees
#39 MeSH descriptor: [Abdomen, Acute] explode all trees
#40 #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39
#41 Recurr*:ti,ab
#42 Chronic*:ti,ab
#43 Intermittent*:ti,ab
#44 Episode*:ti,ab
#45 Bout:ti,ab
#46 Bouts:ti,ab
#47 Spasm*:ti,ab
#48 Transitory:ti,ab
#49 Transient:ti,ab
#50 Functional:ti,ab
#51 Continu*:ti,ab
#52 Paroxysmal:ti,ab
#53 Persistent:ti,ab
#54 Idiopathic:ti,ab
#55 Unspecifi*:ti,ab
#56 Non specifi*:ti,ab
#57 Nonspecific*:ti,ab
#58 Motility:ti,ab
#59 MeSH descriptor: [Recurrence] explode all trees
#60 #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59
#61 #40 and #60
#62 irritable bowel syndrome*:ti,ab
#63 #61 or #62
#64 Child*:ti,ab
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#65 Adolescen*:ti,ab
#66 Boy*:ti,ab
#67 Girl*:ti,ab
#68 teen*:ti,ab
#69 Schoolchild*:ti,ab
#70 Young adult*:ti,ab
#71 Youth*:ti,ab
#72 Pediatric*:ti,ab
#73 Paediatric*:ti,ab
#74 Student*:ti,ab
#75 Pupil*:ti,ab
#76 Juvenile*:ti,ab
#77 Young person*:ti,ab
#78 MeSH descriptor: [Child] explode all trees
#79 MeSH descriptor: [Adolescent] explode all trees
#80 MeSH descriptor: [Young Adult] explode all trees
#81 MeSH descriptor: [Students] explode all trees
#82 #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81
#83 #63 and #82
Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid Medline (1946 to present)
Search dates: 11 April 2013 (6238 records); 11 April 2014 (5957 records); 25 March 2015 (223 records); 9 June 2016 (300 records).
1 stomach*.tw.
2 abdom*.tw.
3 intestin*.tw.
4 viscera*.tw.
5 tummy.tw.
6 bowel*.tw.
7 belly.tw.
8 gastrointestinal.tw.
9 gi.tw.
10 gastric.tw.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 pain*.tw.
13 Ache*.tw.
14 Sore*.tw.
15 Discomfort*.tw.
16 Distress*.tw.
17 Cramp*.tw.
18 Disorder$1.tw.
19 Symptom$1.tw.
20 Migraine$1.tw.
21 Epilep*.tw.
22 syndrome$1.tw.
23 colic*.tw.
24 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 irritable bowel$.tw.
26 ibs.tw.
27 functional dyspepsia.tw.
28 25 or 26 or 27
29 ((stomach* or abdom* or intestin* or viscera* or tummy or bowel* or belly or gastrointestinal or gi or gastric) adj3 (pain* or Ache* or
Sore* or Discomfort* or Distress* or Cramp* or Disorder$1 or Symptom$1 or Migraine$1 or Epilep* or syndrome$1 or colic*)).tw.
30 exp Irritable Bowel Syndrome/
31 exp Colonic Diseases/
32 exp Abdominal Pain/
33 exp Dyspepsia/
34 exp Colic/
35 exp Abdomen, Acute/
36 30 or 31 or 32 or 33 or 34 or 35
37 28 or 29 or 36
38 Recurr*.tw.
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39 Chronic*.tw.
40 Intermittent*.tw.
41 Bout$1.tw.
42 spasm*.tw.
43 Transitory.tw.
44 Transient.tw.
45 Functional.tw.
46 Continu*.tw.
47 Paroxysmal.tw.
48 Persistent.tw.
49 Idiopathic.tw.
50 unspecifi*.tw.
51 Non specifi*.tw.
52 nonspecifi*.tw.
53 motility.tw.
54 episod*.tw.
55 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp Recurrence/
57 55 or 56
58 37 and 57
59 irritable bowel syndrome*.tw.
60 58 or 59
61 randomized controlled trial.pt.
62 controlled clinical trial.pt.
63 randomi#ed.ab.
64 placebo$.ab.
65 randomly.ab.
66 trial.ab.
67 groups.ab.
68 exp animals/ not humans.sh.
69 or/61-67
70 69 not 68
71 60 and 70
72 exp Child/
73 exp Adolescent/
74 exp Young Adult/
75 exp Students/
76 Child*.tw.
77 Adolescen*.tw.
78 Young person*.tw.
79 Boy*.tw.
80 Girl*.tw.
81 teen*.tw.
82 Schoolchild*.tw.
83 Young adult*.tw.
84 Youth*.tw.
85 P*ediatric*.tw.
86 Student*.tw.
87 Pupil*.tw.
88 Juvenile*.tw.
89 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88
90 71 and 89
Embase Ovid (1974 to present)
Search dates: 11 April 2013 (2272 records); 11 April 2014 (2523 records); 25 March 2015 (250 records); 9 June 2016 (345 records).
1 recurr*.tw.
2 chronic*.tw.
3 intermittent*.tw.
4 bout$1.tw.
5 spasm*.tw.
6 transitory.tw.
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7 transient.tw.
8 functional.tw.
9 continu*.tw.
10 paroxysmal.tw.
11 persistent.tw.
12 idiopathic.tw.
13 unspecifi*.tw.
14 non specifi*.tw.
15 nonspecifi*.tw.
16 motility.tw.
17 episod*.tw.
18 or/1-17
19 exp recurrent disease/
20 18 or 19
21 stomach*.tw.
22 abdom*.tw.
23 intestin*.tw.
24 viscera*.tw.
25 tummy.tw.
26 bowel*.tw.
27 belly.tw.
28 gastrointestinal.tw.
29 gi.tw.
30 gastric.tw.
31 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 pain*.tw.
33 Ache*.tw.
34 Sore*.tw.
35 Discomfort*.tw.
36 Distress*.tw.
37 Cramp*.tw.
38 Disorder$1.tw.
39 Symptom$1.tw.
40 Migraine$1.tw.
41 Epilep*.tw.
42 syndrome$1.tw.
43 colic*.tw.
44 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45 irritable bowel$.tw.
46 ibs.tw.
47 functional dyspepsia.tw.
48 45 or 46 or 47
49 ((stomach* or abdom* or intestin* or viscera* or tummy or bowel* or belly or gastrointestinal or gi or gastric) adj3 (pain* or Ache* or
Sore* or Discomfort* or Distress* or Cramp* or Disorder$1 or Symptom$1 or Migraine$1 or Epilep* or syndrome$1 or colic*)).tw.
50 48 or 49
51 exp colic/
52 exp irritable colon/
53 exp abdominal pain/
54 exp dyspepsia/
55 colon disease/
56 50 or 51 or 52 or 53 or 54 or 55
57 20 and 56
58 irritable bowel syndrome*.tw.
59 57 or 58
60 Clinical trial/
61 Randomized controlled trial/
62 Randomization/
63 Single blind procedure/
64 Double blind procedure/
65 Crossover procedure/
66 Placebo/
67 Randomi?ed controlled trial$.tw.
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68 Rct.tw.
69 Random allocation.tw.
70 Randomly allocated.tw.
71 Allocated randomly.tw.
72 (allocated adj2 random).tw.
73 Single blind$.tw.
74 Double blind$.tw.
75 ((treble or triple) adj blind$).tw.
76 Placebo$.tw.
77 Prospective study/
78 or/60-77
79 Case study/
80 Case report.tw.
81 Abstract report/ or letter/
82 or/79-81
83 78 not 82
84 59 and 83
85 exp Child/
86 exp Adolescent/
87 exp Young Adult/
88 exp Students/
89 Child*.tw.
90 Adolescen*.tw.
91 Young person*.tw.
92 Boy*.tw.
93 Girl*.tw.
94 teen*.tw.
95 Schoolchild*.tw.
96 Young adult*.tw.
97 Youth*.tw.
98 P*ediatric*.tw.
99 Student*.tw.
100 Pupil*.tw.
101 Juvenile*.tw.
102 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101
103 84 and 102
CINAHL Healthcare Databases Advanced Search (Cumulative Index to Nursing and Allied Health Literature; 1981 to present)
Search dates: 18 April 2013 (175 records); 11 April 2014 (195 records); 26 March 2015 (21 records); 9 June 2016 (11 records).
1. CINAHL; recurr*.ti,ab;
2. CINAHL; chronic*.ti,ab;
3. CINAHL; intermittent*.ti,ab;
4. CINAHL; (bout OR bouts).ti,ab;
5. CINAHL; spasm*.ti,ab;
6. CINAHL; transitory.ti,ab;
7. CINAHL; transient.ti,ab;
8. CINAHL; functional.ti,ab;
9. CINAHL; continu*.ti,ab;
10. CINAHL; paroxysmal.ti,ab;
11. CINAHL; persistent.ti,ab;
12. CINAHL; idiopathic.ti,ab;
13. CINAHL; unspecifi*.ti,ab;
14. CINAHL; "non specifi*".ti,ab;
15. CINAHL; nonspecifi*.ti,ab;
16. CINAHL; motility.ti,ab;
17. CINAHL; episod*.ti,ab;
18. CINAHL; exp RECURRENCE/;
19. CINAHL; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18;
20. CINAHL; stomach*.ti,ab;
21. CINAHL; abdom*.ti,ab;
22. CINAHL; intestin*.ti,ab;
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23. CINAHL; viscera*.ti,ab;
24. CINAHL; tummy.ti,ab;
25. CINAHL; bowel*.ti,ab;
26. CINAHL; belly.ti,ab;
27. CINAHL; gastrointestinal.ti,ab;
28. CINAHL; gi.ti,ab;
29. CINAHL; gastric.ti,ab;
30. CINAHL; 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29;
31. CINAHL; pain*.ti,ab;
32. CINAHL; Ache*.ti,ab;
33. CINAHL; Sore*.ti,ab;
34. CINAHL; Discomfort*.ti,ab;
35. CINAHL; Distress*.ti,ab;
36. CINAHL; Cramp*.ti,ab;
37. CINAHL; (Disorder OR Disorders).ti,ab;
38. CINAHL; (Symptom OR Symptoms).ti,ab;
39. CINAHL; (Migraine OR Migraines).ti,ab;.
40. CINAHL; Epilep*.ti,ab;
41. CINAHL; (syndrome OR syndromes).ti,ab;
42. CINAHL; colic*.ti,ab;
43. CINAHL; 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42;
44. CINAHL; 30 AND 43;
45. CINAHL; "irritable bowel*".ti,ab;
46. CINAHL; ibs.ti,ab;
47. CINAHL; "functional dyspepsia".ti,ab;
48. CINAHL; exp COLIC/;
49. CINAHL; exp IRRITABLE BOWEL SYNDROME/;
50. CINAHL; exp COLONIC DISEASES, FUNCTIONAL/;
51. CINAHL; exp ABDOMINAL PAIN/;
52. CINAHL; exp DYSPEPSIA/;
53. CINAHL; 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52;
54. CINAHL; 44 OR 53;
55. CINAHL; 19 AND 54;
56. CINAHL; (irritable AND bowel AND syndrome*).ti,ab;
57. CINAHL; 55 OR 56;
58. CINAHL; Child*.ti,ab;
59. CINAHL; Adolescen*.ti,ab;
60. CINAHL; "Young person*".ti,ab;
61. CINAHL; Boy*.ti,ab;
62. CINAHL; Girl*.ti,ab;
63. CINAHL; teen*.ti,ab;
64. CINAHL; Schoolchild*.ti,ab;
65. CINAHL; "Young adult*".ti,ab;
66. CINAHL; Youth*.ti,ab;
67. CINAHL; Student*.ti,ab;
68. CINAHL; Pupil*.ti,ab;
69. CINAHL; Juvenile*.ti,ab;
70. CINAHL; exp CHILD/;
71. CINAHL; exp STUDENTS/;
72. CINAHL; 70 OR 71;
73. CINAHL; Pediatric*.ti,ab;
74. CINAHL; Paediatric*.ti,ab;
75. CINAHL; 67 OR 68 OR 69 OR 72 OR 73 OR 74;
76. CINAHL; 63 OR 64 OR 65 OR 66;
77. CINAHL; 58 OR 59 OR 60 OR 61 OR 62;
78. CINAHL; 70 OR 73 OR 74 OR 75;
79. CINAHL; 57 AND 78;
80. CINAHL; exp RANDOMIZED CONTROLLED TRIALS/;
81. CINAHL; random*.ti,ab;
82. CINAHL; "clin* trial*".ti,ab;
83. CINAHL; (singl* OR doubl* OR tripl* OR trebl*).ti,ab;
84. CINAHL; (mask* OR blind*).ti,ab;
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85. CINAHL; 83 AND 84;
86. CINAHL; "random* allocate*".ti,ab;
87. CINAHL; "random assign*".ti,ab;
88. CINAHL; exp RANDOM ASSIGNMENT/;
89. CINAHL; exp CLINICAL TRIALS/;
90. CINAHL; exp META ANALYSIS/;
91. CINAHL; 88 OR 89 OR 90;
92. CINAHL; 80 OR 81 OR 82 OR 85 OR 86 OR 87;
93. CINAHL; 91 OR 92;
94. CINAHL; 79 AND 93;
PsycINFO Ovid (1806 to present)
Search dates: 18 April 2013 (238 records); 11 April 2014 (757 records); 25 March 2015 (47 records); 9 June 2016 (87 records).
1 stomach*.tw.
2 abdom*.tw.
3 intestin*.tw.
4 viscera*.tw.
5 tummy.tw.
6 bowel*.tw.
7 belly.tw.
8 gastrointestinal.tw.
9 gi.tw.
10 gastric.tw.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 pain*.tw.
13 Ache*.tw.
14 Sore*.tw.
15 Discomfort*.tw.
16 Distress*.tw.
17 Cramp*.tw.
18 Disorder$1.tw.
19 Symptom$1.tw.
20 Migraine$1.tw.
21 Epilep*.tw.
22 syndrome$1.tw.
23 colic*.tw.
24 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 irritable bowel$.tw.
26 ibs.tw.
27 functional dyspepsia.tw.
28 25 or 26 or 27
29 ((stomach* or abdom* or intestin* or viscera* or tummy or bowel* or belly or gastrointestinal or gi or gastric) adj3 (pain* or Ache* or
Sore* or Discomfort* or Distress* or Cramp* or Disorder$1 or Symptom$1 or Migraine$1 or Epilep* or syndrome$1 or colic*)).tw.
30 exp Irritable Bowel Syndrome/
31 exp Dyspepsia/
32 recurr*.tw.
33 chronic*.tw.
34 intermittent*.tw.
35 bout$1.tw.
36 spasm*.tw.
37 transitory.tw.
38 transient.tw.
39 functional.tw.
40 continu*.tw.
41 paroxysmal.tw.
42 persistent.tw.
43 idiopathic.tw.
44 unspecifi*.tw.
45 non specifi*.tw.
46 nonspecifi*.tw.
47 motility.tw.
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48 episod*.tw.
49 or/32-48
50 irritable bowel syndrome*.tw.
51 exp Students/
52 Child*.tw.
53 Adolescen*.tw.
54 Young person*.tw.
55 Boy*.tw.
56 Girl*.tw.
57 teen*.tw.
58 Schoolchild*.tw.
59 Young adult*.tw.
60 Youth*.tw.
61 P*ediatric*.tw.
62 Student*.tw.
63 Pupil*.tw.
64 Juvenile*.tw.
65 28 or 29 or 30 or 31
66 49 and 65
67 50 or 66
68 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64
69 67 and 68
ERIC ProQuest (Education Resources Information Center; 1966 to present)
Search dates: 19 April 2013 (276 records); 11 April 2014 (294 records); 26 March 2015 (0 records); 9 June 2016 (2 records).
(ab,ti(Pain*) OR ab,ti(Ache*) OR ab,ti(Sore*) OR ab,ti(Discomfort*) OR ab,ti(Distress*) OR ab,ti(Cramp*) OR ab,ti(Disorder) OR ab,ti(Disorders)
OR ab,ti(Symptom*) OR ab,ti(Migraine*) OR ab,ti(Epilep*) OR ab,ti(Colic*) OR ab,ti(Syndrome*))
AND
(Ab,ti(Recurr*) OR ab,ti(Chronic*) OR ab,ti(Intermittent*) OR ab,ti(Episode*) OR ab,ti(Bout) OR ab,ti(Bouts) OR ab,ti((Spasm*) OR
ab,ti(Transitory) OR ab,ti(Transient) OR ab,ti(Functional) OR ab,ti(Continu*) OR ab,ti(paroxysmal) OR ab,ti(Persistent) OR ab,ti (Idiopathic)
OR ab,ti(Unspecifi*) OR ab,ti(Non specifi*) OR ab,ti(motility) OR SU.EXACT.EXPLODE("Recurrence"))
AND
(Ab,ti(Stomach*) OR ab,ti(Abdom*) OR ab,ti(Sore*) OR ab,ti(Intestin*) OR ab,ti(Viscera*) OR ab,ti(Tummy) OR ab,ti(Bowel*) OR ab,ti(Belly)
OR ab,ti(Gastrointestinal) OR ab,ti(GI) OR ab,ti(Epilep*) OR ab,ti(Gastric))
OR
(Ab,ti(irritable bowel*) OR ab,ti(ibs) OR ab,ti(colonic disease*) OR ab,ti(functional dyspepsia))
British Education Index ProQuest (1975 to present)
Search dates: 19 April 2013 (46 records); 11 April 2014 (48 records); 26 March 2015 (0 records); 9 June 2016 (5 records).
((ab,ti(Stomach*) OR ab,ti(Abdom*) OR ab,ti(Intestin*) OR ab,ti(Viscera*) OR ab,ti(Tummy) OR ab,ti(Bowel*) OR ab,ti(Belly) OR
ab,ti(Gastrointestinal) OR ab,ti(GI) OR ab,ti(Gastric))
AND
((ab,ti(Pain*) OR ab,ti(Ache*) OR ab,ti(Sore*) OR ab,ti(Discomfort*) OR ab,ti(Distress*) OR ab,ti(Cramp*) OR ab,ti(Disorder) OR
ab,ti(Disorders) OR ab,ti(Symptom) OR OR ab,ti(Symptoms) OR ab,ti(Migraine) OR ab,ti(Migraines) OR ab,ti(Epilep*) OR ab,ti(Colic*) OR
ab,ti(Syndrome) OR ab,ti(Syndromes))
OR
(Ab,ti(irritable bowel*) OR ab,ti(ibs) OR ab,ti(Functional dyspepsia))
Applied Social Sciences Index and Abstracts ProQuest (ASSIA; 1987 to present)
Search dates: 19 April 2013 (179 records); 11 April 2014 (545 records); 26 March 2015 (27 records); 9 June 2016 (48 records).
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((ab,ti(Stomach*) OR ab,ti(Abdom*) OR ab,ti(Intestin*) OR ab,ti(Viscera*) OR ab,ti(Tummy) OR ab,ti(Bowel*) OR ab,ti(Belly) OR
ab,ti(Gastrointestinal) OR ab,ti(GI) OR ab,ti(gastric)
AND
(ab,ti(Pain*) OR ab,ti(Ache*) OR ab,ti(Sore*) OR ab,ti(Discomfort*) OR ab,ti(Distress*) OR ab,ti(Cramp*) OR ab,ti(Disorder) OR ab,ti(Disorders)
OR ab,ti(Symptom*) OR ab,ti(Symptoms) OR ab,ti(Migraine*) OR ab,ti(Epilep*) OR ab,ti(Syndrome) OR ab,ti(Syndromes) OR ab,ti(colic*)
AND
(ab,ti(Recurr*) OR ab,ti(Chronic*) OR ab,ti(Intermittent*) OR ab,ti(Episode*) OR ab,ti(Bout) OR ab,ti(bouts) OR ab,ti(Spasm*) OR
ab,ti(Transitory) OR ab,ti(Transient) OR ab,ti(Functional) OR ab,ti(Continu*) OR ab,ti(Paroxysmal) OR ab,ti(Persistent) OR ab,ti(Idiopathic)
OR ab,ti(Unspecifi*) OR ab,ti(Non specifi*) OR ab,ti(motility))
OR
(ab,ti(irritable bowel) OR ab,ti(ibs) OR ab,ti(functional dyspepsia))
Allied and Complementary Medicine Healthcare Databases Advanced Search (AMED; 1985 to present)
Search dates: 18 April 2013 (63 records); 11 April 2014 (74 records); 25 March 2015 (1 record); 9 June 2016 (1 record).
1. AMED; Recurr*.ti,ab;
2. AMED; Chronic*.ti,ab;
3. AMED; Intermittent*.ti,ab;
4. AMED; Episod*.ti,ab;
5. AMED; (Bout OR Bouts).ti,ab;
6. AMED; Spasm*.ti,ab;
7. AMED; Transitory.ti,ab;
8. AMED; Transient.ti,ab;
9. AMED; Functional.ti,ab;
10. AMED; Continu*.ti,ab;
11. AMED; Paroxysmal.ti,ab;
12. AMED; Persistent.ti,ab;
13. AMED; Idiopathic.ti,ab;
14. AMED; Unspecifi*.ti,ab;
15. AMED; "Non specifi*".ti,ab;
16. AMED; Nonspecific*.ti,ab;
17. AMED; Motility.ti,ab;
18. AMED; exp RECURRENCE/;
19. AMED; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18;.
20. AMED; Pain*.ti,ab;
21. AMED; Ache*.ti,ab;
22. AMED; Sore*.ti,ab;
23. AMED; Discomfort*.ti,ab;
24. AMED; Distress*.ti,ab;
25. AMED; Cramp*.ti,ab;
26. AMED; (Disorder OR Disorders).ti,ab;
27. AMED; (Symptom OR Symptoms).ti,ab;
28. AMED; (Migraine OR Migraines).ti,ab;
29. AMED; Epilep*.ti,ab;
30. AMED; Colic*.ti,ab;
31. AMED; (Syndrome OR Syndromes).ti,ab;
32. AMED; 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31;
33. AMED; Stomach*.ti,ab;
34. AMED; Abdom*.ti,ab;
35. AMED; Intestin*.ti,ab;
36. AMED; Viscera*.ti,ab;
37. AMED; Tummy.ti,ab;
38. AMED; Bowel*.ti,ab;
39. AMED; Belly.ti,ab;
40. AMED; Gastrointestinal.ti,ab;
41. AMED; GI.ti,ab;
42. AMED; Gastric.ti,ab;
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43. AMED; 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42;
44. AMED; 32 AND 43;
45. AMED; "Colonic disease*".ti,ab;
46. AMED; "Irritable bowel".ti,ab;
47. AMED; IBS.ti,ab; 86
48. AMED; "Functional dyspepsia".ti,ab;
49. AMED; exp IRRITABLE BOWEL SYNDROME/;
50. AMED; exp COLONIC DISEASE/;
51. AMED; exp ABDOMINAL PAIN/;
52. AMED; exp DYSPEPSIA/;
53. AMED; 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52;
54. AMED; 44 OR 53;
55. AMED; 19 AND 54;
56. AMED; (irritable AND bowel AND syndrome*).ti,ab;
57. AMED; Child*.ti,ab;
58. AMED; Adolescen*.ti,ab;
59. AMED; Boy*.ti,ab;
60. AMED; Girl*.ti,ab;
61. AMED; teen*.ti,ab;
62. AMED; Schoolchild*.ti,ab;
63. AMED; "Young adult*".ti,ab;
64. AMED; Youth*.ti,ab; 767 results.
65. AMED; (Pediatric* OR Paediatric*).ti,ab;
66. AMED; Student*.ti,ab;
67. AMED; Pupil*.ti,ab;
68. AMED; Juvenile*.ti,ab;
69. AMED; "Young person*".ti,ab;
70. AMED; exp CHILD/;
71. AMED; exp ADOLESCENT/;
72. AMED; exp STUDENTS/;
73. AMED; 57 OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64 OR 65 OR 66 OR 67 OR 68 OR 69 OR 70 OR 71 OR 72;
74 AMED; 55 OR 56;
75. AMED; 74 AND 73;
LILACS (Latin American and Caribbean Health Science Information database; lilacs.bvsalud.org/en; all available years)
Search dates: 19 April 2013 (11 records); 11 April 2014 (13 records); 26 March 2015 (0 records); 9 June 2016 (0 records).
((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh
double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex
E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple
$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) (trial$ OR ensa$ OR estud$ OR experim$ OR investiga$ OR singl
$ OR simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw
mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw
aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR
Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal
AND NOT (Ct human and Ct animal))) [Palavras]
and ((recurr$ or chronic$ or intermittent$ or bout or bouts or spasm$ or transitory or transient or functional or continu$ or Paroxysmal
or Persistent or Idiopathic or unspecifi$ or Non specifi$ or nonspecific$ or motility or episode$) [Palavras] and (pain$ or ache$ or sore$ or
discomfort$ or distress$ cramp$ or colic$ or disorder or disorders or symptom or symptoms or Migraine$ or Epilep* or syndrome$) and
(stomach$ or abdom$ or intestin$ or viscera$ or tummy$ or bowel$ or belly or gastrointestinal or gi or gastric)) [Palavras]
OpenGrey (www.opengrey.eu; 1980 to present)
Search dates : 19 April 2013 (1 record); 11 April 2014 (1 record); 26 March 2015 (0 records); 9 June 2016 (0 records).
Irritable bowel syndrom*
Ibs
functional dyspepsia
Chronic* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Recurr* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Intermittent* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Bout* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Pharmacological interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
spasm* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Transitory AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Transient AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Functional AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Continu* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Paroxysmal AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Persistent AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Idiopathic AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
unspecifi* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
Non specifi* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
nonspecifi* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
motility AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
episod* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
ClinicalTrials.gov (clinicaltrials.gov; 2007 to present)
Search dates: 11 April 2014 (69 records); 26 March 2015 (35 records); 9 June 2016 (62 records).
“irritable bowel” OR “abdominal pain” in the condition field. Limited to children.
World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; apps.who.int/trialsearch; 1999 to present)
Search dates: 11 April 2014 (106 records); 26 March 2015 (4 records); 9 June 2016 (32 records).
“irritable bowel” OR “abdominal pain” in the condition field. Limited to children and interventional studies.
Appendix 2. Additional methods
We detailed methods for each of the topics below in our protocol (Martin 2014a), but did not use them in the review because we had
insuHicient data to perform a meta-analysis.
• Types of outcome measures.• Unit of analysis issues.• Dealing with missing data.• Assessment of heterogeneity.• Assessment of reporting bias.• Data synthesis.• Subgroup analysis and investigation of heterogeneity.• Sensitivity analysis.
We describe these methods, which have been archived for use in future updates of this review, in the table below.
 
Types of outcome measures
We expect studies to vary in their duration of postintervention follow-up. We will therefore group studies according to duration of fol-
low-up: immediate outcome measurement, short term (less than three months), medium term (three to 12 months), and long term
(greater than 12 months).
Unit of analysis issues
If we find the following three types of trials, we will consider their results as per guidance in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011c, section 9.3).
Cross-over trials
For cross-over trials with random allocation to period and an appropriate washout period, we will include the relevant effect esti-
mate within the meta-analysis, using the generic inverse variance method in Review Manager 5 (Review Manager 2014). An appropri-
ate washout period may vary with the interventions (including drug pharmacokinetics) and outcome measurements. Considering
that RAP can be a stable and chronic condition, a washout period of several weeks may be sufficient.
Cluster-RCTs
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Cluster-randomised trials randomise groups of people rather than individuals. For each cluster-randomised trial, we will first deter-
mine whether or not the data incorporate sufficient controls for clustering (such as robust standard errors or hierarchical linear mod-
els). If data do not have proper controls, then we will attempt to obtain an appropriate estimate of the data's intracluster correlation
coefficient. If we cannot find an estimate in the trial report, then we will request an estimate from the trial report authors. If the au-
thors do not provide an estimate, if possible, we will obtain one from a similar study and conduct a sensitivity analysis to determine if
the results are robust when different values are imputed. We will do this according to procedures described in Higgins 2011c (section
9.3). This will prevent the meta-analysis from being based on clustered data that has not been properly controlled.
Trials with multiple intervention groups
This is a common scenario. To avoid any unit of analysis errors in the meta-analysis, we will use the following approach for a study
that could contribute multiple comparisons.
• We will only analyse the interventions together if they are clinically similar, that is testing the same class of drug. In this situation
we will not split the control group, but instead will combine the intervention groups to enable a single pair-wise comparison for the
meta-analysis. If the interventions are similar enough to be in a single meta-analysis but cannot be combined, then we will split the
control group.• If the interventions are not similar, we will perform separate meta-analyses. Consequently, a single study could contribute data to
different meta-analyses (e.g. if the interventions involve eliminating different classes of drugs); this does not require the control
group to be split.
We will not perform a multiple-treatment meta-analysis, as the clinical heterogeneity would mean the results have little clinical
meaning.
Dealing with missing data
We may carry out a sensitivity analysis to establish if the inclusion of studies with high levels of missing data significantly alters the
findings of the review.
Assessment of reporting bias
Publication bias
If we identify sufficient trials (at least 10), we will use the outcome data to produce a funnel plot to investigate the likelihood of overt
publication bias (Sutton 2000). Any asymmetry of the funnel plot may indicate possible publication bias. We will explore other rea-
sons for asymmetry such as poor methodological quality or heterogeneity. We will look for publication bias by comparing the results
of the published and unpublished data.
Assessment of heterogeneity
We will describe statistical heterogeneity (observed variability in study results that is greater than that expected to occur by chance)
by calculating I2 (Higgins 2003). I2 describes approximately the proportion of variation in point estimates due to heterogeneity rather
than sampling error. An I2 more than 50% may indicate significant heterogeneity.
We will use a Chi2 test to further assess the role of heterogeneity on the strength of the evidence. We will regard any result with a P
value lower than 0.10 as indicative of heterogeneity. We will interpret this cautiously and use it to help quantify the impact of hetero-
geneity on the results of the meta-analysis (Higgins 2003).
Data synthesis
We will use Review Manager 5 for statistical analysis (Review Manager 2014). Two review authors (RAA, AB, JTC, TVND, or AEM) will in-
dependently enter data into Review Manager 5. We will report summary statistics for continuous data as mean differences or stan-
dardised mean differences using a random-effects model. For dichotomous data, we will report odds ratios using a random-effects
model. We intend to use a a random-effects model as we anticipate significant statistical and clinical heterogeneity.
Subgroup analysis and investigation for heterogeneity
If sufficient trials are available, we will examine the following subgroups to explore clinical heterogeneity:
• type of RAP (as defined by the Rome III criteria) (Rasquin 2006);• age; and
  (Continued)
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• duration of follow-up: immediate outcome measurement, short term (less than three months), medium term (three to 12 months),
and long term (greater than 12 months).
Subgroup analysis can be misleading because the studies may not be designed and powered to show difference within subgroups.
We will therefore undertake subgroup analyses with caution.
Sensitivity analysis
We will conduct primary analyses based on available data on the outcomes of interest. Following this, we will use a sensitivity analy-
sis to assess the robustness of conclusions in relation to two aspects of study design:
1. the effect of inadequate allocation concealment, by the removal of studies judged to be at high or unclear risk of bias for that domain;
and
2. the effect of inadequate blinding to treatment allocation by outcome assessors, by the removal of studies judged to be at high or
unclear risk of bias for that domain.
We will also conduct a sensitivity analysis to establish the effect of missing data on the estimate of treatment effect, by performing
the analysis with and without the studies with significant missing data to determine if this alters the conclusions.
  (Continued)
 
Footnotes
RAP: recurrent abdominal pain
RCT: randomised controlled trial
W H A T ' S   N E W
 
Date Event Description
10 June 2016 New citation required and conclusions
have changed
Following a new search in April 2013 and updated searches in
April 2014, March 2015, and June 2016, we added 13 new studies.
31 January 2015 New search has been performed The review supersedes the previous version, following a new
protocol and new search up to June 2016 (see Published notes).
 
C O N T R I B U T I O N S   O F   A U T H O R S
• Review design: AEM, SL• Review co-ordination: AEM• Data collection:* Search strategy design: AEM, AB* Searches undertaken: AEM, AB* Search results screened: AEM, TVND, RAA, AB, JTC, RW* Retrieval of papers: AEM, AB* Paper screening and appraisal, and extraction of data: AEM, TVND, RAA, AB, JTC, RW* Writing to authors for additional information: AEM, AB, RAA, TVND* Entering the data into Review Manager 5: AEM, TVND, RAA, AB, JTC• Analysis of the data: AEM, TVND, RAA, AB, JTC, SL• Interpretation of the data:* Methodological perspective: AEM, TVND, RAA, AB, JTC* Clinical perspective: AEM, TVND, SL
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